Wednesday, 09. April 2014

08:00-11:00  EASL-IASL (International Association for the Study of the Liver): ACUTE LIVER FAILURE/ ACUTE ON CHRONIC LIVER FAILURE: PERSPECTIVE OF THE EAST AND THE WEST

F. Villamil, , Argentina
L. Castéra, Service d'Hépatologie, Hôpital Beaujon, France

OVERVIEW ON VIRAL HEPATITIS

08:00-08:20  ACUTE LIVER FAILURE IN THE WEST

J. Wendon, , United Kingdom

DIAGNOSIS AND STAGING IN CHRONIC VIRAL HEPATITIS

08:20-08:40  ACUTE LIVER FAILURE IN THE EAST

S. Acharya, , India

08:40-09:00  ACUTE ON CHRONIC LIVER FAILURE IN CHINA

F.-S. Wang, , China

09:00-09:15  CASE PRESENTATION

R. Reddy, , United States

09:15-09:30  Q&A

09:30-10:00  COFFEE BREAK

10:00-10:30  STATE-OF-THE-ART LECTURE - INTRODUCTION:

S. Lee, , Canada

10:30-11:00  HEMOCHROMATOSIS: EVOLUTION FROM CLINICAL DIAGNOSIS TO GENETICS

L. Powell, , Australia

Joint Workshop, ICC Capital Hall

08:00-11:00  ILC (VIRAL HEPATITIS WORKSHOP) JOINT WORKSHOP

J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France

08:00-08:20  MANAGEMENT OF HBV DURING PREGNANCY

P. Lampertico, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy

08:20-08:40  HBV THERAPY AND IATROGENIC IMMUNE SUPPRESSION

A. Lok, , United States

08:40-09:00  DOES HBV THERAPY REDUCE THE RISK OF HEPATOCELLULAR CARCINOMA?

F. Zoulim, INSERM Unit 871, France

09:00-09:20  NEW HCV THERAPIES: SOLVED ISSUES

J. Feld, Toronto Western Hospital Liver Centre, Canada

09:20-09:30  DISCUSSION

09:30-10:00  COFFEE BREAK

10:00-10:20  NEW HCV THERAPIES: UNSOLVED ISSUES

J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France
10:20-10:40  UPDATE ON HEV
H. Dalton, , United Kingdom

10:40-11:00  DISCUSSION

Joint Workshop, Capital Suite 7-8-9

08:00-11:00  EASL-ELITA (European Liver and Intestine Transplant Association) - ILTS (International Liver Transplantation Society) - LICAGE (Liver Intensive Care Group of Europe) JOINT WORKSHOP
P. Burra, Padova University Hospital, Italy
R. Freeman, , United States
P. Muiesan, University of Birmingham, United Kingdom
A. Lee, Royal Infirmary of Edinburgh, United Kingdom

08:00-08:20  OVERVIEW OF METABOLIC SYNDROME INCLUDING INCREASING INDICATION FOR LIVER TRANSPLANTATION
E. Bugianesi, University Of Torino, Italy

08:20-08:40  NAFLD AND THE RISK OF HCC
P. Newsome, , United Kingdom

08:40-09:00  ASSESSMENT OF PATIENTS WITH METABOLIC SYNDROME BEFORE LIVER TRANSPLANTATION
N. Snook, , United Kingdom

09:00-09:20  THE OTHER SIDE OF THE COIN: INCREASED INCIDENCE OF TRANSPLANTATION OF FATTY LIVERS
N. Gilbo, , Belgium

09:20-09:30  DISCUSSION

09:30-09:50  COFFEE BREAK

09:50-10:05  CRITICAL CARE MANAGEMENT OF OBESE PATIENTS UNDERGOING LIVER TRANSPLANTATION
P. Neligan, , Ireland

10:05-10:20  BARIATRIC SURGERY BEFORE, DURING AND AFTER LIVER TRANSPLANTATION
R. Prasad, , United Kingdom

10:20-10:35  SURGICAL CHALLENGES OF LIVER TRANSPLANT IN THE MORBIDLY OBESE
J. Heimback, , United States

10:35-10:50  PREVENTION OF NAFLD/NASH RECURRENCE AND MANAGEMENT OF METABOLIC SYNDROME AFTER LIVER TRANSPLANTATION IN ADULTS AND ADOLESCENTS
M. Charlton, Mayo Clinic, United States

10:50-11:00  DISCUSSION

Joint Workshop, Capital Suite 11-12

08:00-11:00  EASL-ILCA (The International Liver Cancer Association) JOINT WORKSHOP
M. Peck-Radosavljevic, , Austria
P. Galle, , Germany
08:00-08:30  LIQUID VS. TISSUE BIOPSY: THE FUTURE OF MOLECULAR HCC DIAGNOSTICS?
P. Schirmacher, , Germany

08:30-09:00  ILCA GUIDELINES OF MANAGEMENT OF INTRAHEPATIC CHOLANGIOCARCINOMA
G. Gores, , United States

09:00-09:30  NOVEL DRIVERS AND TARGETED THERAPIES IN HCC
J.M. Llovet, CIBERehd, Hospital Clinic Barcelona, Spain

09:30-10:00  COFFEE BREAK

10:00-10:30  CHALLENGES FOR FIRST-LINE THERAPIES IN INTERMEDIATE AND ADVANCED HCC
P. Galle, , Germany

10:30-11:00  REVISITING SECOND-LINE TREATMENTS
M. Peck-Radosavljevic, , Austria

08:00-11:00  EASL-ESPGHAN (The European Society for Paediatric Gastroenterology, Hepatology and Nutrition) JOINT WORKSHOP
F. Lammert, Saarland University Hospital, Germany
L. D'Antiga, Ospedali Riuniti Bergamo, Italy

08:00-08:30  WHAT ADULT HEPATOLOGIST NEEDS TO KNOW ABOUT PAEDIATRIC METABOLIC CONDITIONS (BUT DOES NOT DARE TO ASK) ?
V. McLin, , Switzerland

08:30-09:00  THE PATIENT WITH DIET-CONTROLLED METABOLIC LD
D. Dobbelaere, , France

09:00-09:30  DEVELOPMENT OF MALIGNANCY IN METABOLIC DISORDERS
U. Baumann, , Germany

09:30-10:00  COFFEE BREAK

10:00-10:30  METABOLIC INDICATIONS FOR LT
P. McKiernan, , United Kingdom

10:30-11:00  ALFA-1-ANTITRYPSIN DEFICIENCY - WHO NEEDS TO BE LIVER TRANSPLANTED LATE IN LIFE?
D. Hadzic, , United Kingdom

08:00-11:00  EASL-FLIP (Fatty Liver: Inhibition of Progression) JOINT WORKSHOP
H. Reeves, Newcastle University Medical School, United Kingdom
V. Ratziu, Hopital Pitié Salpêtrière, France

HIGHLIGHTS FROM THE FLIP PROJECT

08:00-08:20  MICROBIOTA AS A DRIVER OF LIVER FIBROGENESIS
G. Svegiati-Baroni, , Italy

08:20-08:30  DISCUSSION

08:30-08:50  KLF6 - THE OTHER GENETIC PLAYER IN NASH
H. Reeves, Newcastle University Medical School, United Kingdom
08:50-09:00  DISCUSSION

CLINICAL HOTSPOTS

09:00-09:20  NAFLD IN ASIA-PACIFIC: A WESTERN DISEASE GOING GLOBAL?
J. George, Australia

09:20-09:30  DISCUSSION

09:30-09:50  COFFEE BREAK

09:50-10:10  CAN WE PREDICT MORTALITY AND DISEASE PROGRESSION IN NAFLD?
S. Harrisson, United States

10:10-10:20  DISCUSSION

THERAPEUTIC ADVANCES

10:20-10:40  CURRENT CLINICAL TRIALS AND PROMISING DRUGS
V. Ratziu, Hopital Pitié Salpêtrière, France

10:40-10:50  DISCUSSION

10:50-11:00  GENERAL DISCUSSION AND CLOSING REMARKS
V. Ratziu, Hopital Pitié Salpêtrière, France
H. Reeves, Newcastle University Medical School, United Kingdom

08:00-11:00  EASL-HEPACUTE/SPHINX JOINT WORKSHOP

G. Papatheodoridis, Athens University Medical School, Hippokration Hospital, Greece
D. Duffy, France

HCV GENOTYPE 4 - A PREVIOUSLY NEGLECTED AND UNDER-STUDIED DISEASE

08:00-08:05  INTRODUCTION AND STATEMENT OF OBJECTIVES
H. Diepolder, Germany
G. Papatheodoridis, Athens University Medical School, Hippokration Hospital, Greece
D. Duffy, France

08:05-08:25  THE EPIDEMIOLOGY OF HCV GENOTYPE 4
D. Lavanchy, Switzerland

08:25-08:45  THE SEQUENCE DIVERSITY OF HCV GENOTYPE 4
P. Simmonds, United Kingdom

NEW INSIGHTS INTO HCV GENOTYPE 4 FROM THE SPHINX AND HEPACUTE RESEARCH NETWORKS

08:45-08:53  HCV G4 VIRAL SEQUENCES
B. Bartosch, France

08:53-09:01  DISCRIMINATION OF ACUTE AND CHRONIC HCV PATIENTS USING A MULTIPLEXED SEROLOGICAL ASSAY
N. Schneiderhan-Marra, Germany

09:01-09:09  HCVG4 SPECIFIC T CELL RESPONSES DURING ACUTE HEPATITIS
S. Abdelwahab, Egypt

09:09-09:17  POINT OF CARE HCV ASSAYS
D. Duffy, France

09:17-09:30  JOINT QUESTIONS / DISCUSSION
09:30-10:00 COFFEE BREAK

HCV GENOTYPE 4 - HOPE FOR THE FUTURE

10:00-10:20 BROAD SPECTRUM DIRECT ACTING ANTIVIRALS FOR HCVG4
G. Esmat, , Egypt

10:20-10:40 IMPROVING ACCESS TO TREATMENT OF HCVG4- LESSONS FROM HIV
N. Ford, , United Kingdom

10:40-11:00 JOINT QUESTIONS / DISCUSSION

08:00-11:00 EASL-PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa) - MSF (Médecins Sans Frontières) JOINT WORKSHOP
M. Thursz, , United Kingdom
M. Kazatchkine, , Switzerland

08:00-08:25 CONTROLLING THE HCV EPIDEMIC THROUGH INTERRUPTION OF TRANSMISSION
A. Fontanet, Institut Pasteur, France

08:25-08:50 CONTROLLING THE HBV EPIDEMIC THROUGH VACCINATION: SUCCESSES AND CHALLENGES IN RESOURCE-LIMITED SETTINGS
D.-S. Chen, , Taiwan

08:50-09:30 PANEL DISCUSSION: SCREENING FOR HBV & HCV IN SUB-SAHARAN AFRICA AND POINT-OF-CARE DIAGNOSTICS
M. Lemoine, Imperial College London, St Mary's Hospital, United Kingdom
P. Duneton, , Switzerland

09:30-10:00 COFFEE BREAK

10:00-10:30 UNIVERSAL ACCESS TO ANTIVIRAL MEDICATION – CHALLENGES FOR THE HEPATITIS PATIENT
C. Gore, , United Kingdom

10:30-11:00 HOW TO ACCESS PWID FOR SCREENING AND TREATMENT
P. Bruggmann, Arud Centres for Addiction Medicine, Switzerland

08:00-11:00 EASL-ESBRA (The European Society for Biomedical Research on Alcoholism) JOINT WORKSHOP
J.-F. Dufour, , Switzerland
H.K. Seitz, Salem Medical Centre, Germany

08:00-08:30 ALCOHOL DEPENDENCY - DIAGNOSTIC AND TREATMENT
A. Gual, , Spain

08:30-09:00 ALCOHOL AND EXTRA HEPATIC DISEASES
J. Fernandez-Sola, , Spain

09:00-09:30 MACROPHAGES IN ALCOHOLIC HEPATITIS
T. Morgan, , United States

09:30-10:00 COFFEE BREAK
**NEW DIAGNOSTIC APPROACHES TO ALCOHOLIC LIVER DISEASE: TO THE ROLE OF IRON**
S. Mueller, Department of Internal Medicine, Salem Medical Center and Center for Alcohol Research, University of Heidelberg, Germany

**THERAPY OF ALCOHOLIC LIVER DISEASE**
A. Louvet, Hôpital Huriez, France

**EASL-VALDIG (Vascular Liver Disease) JOINT WORKSHOP**
J.C. Garcia Pagan, Spain
D.-C. Valla, France

**MICROPARTICLES: INTRAVASCULAR MESSENGERS CAUSING PROGRESSION OF LIVER DISEASE**
P.-E. Rautou, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, France

**SOS IN THE NON-BONE MARROW TRANSPLANT SETTING**
L. Rubbia-Brandt, Switzerland

**NEW ANTICOAGULANTS: PRO AND CONS IN LIVER PATIENTS**
T. Lisman, Netherlands

**COFFEE BREAK**

**IDIOPATHIC PORTAL HYPERTENSION. DIAGNOSIS AND CLINICAL MANIFESTATIONS**
S. Seijo, Spain

**RENDU-OSLER. MANAGEMENT ACCORDING TO MANIFESTATIONS. WHEN TO TRANSPLANT?**
E. Buscarini, Italy

**EASL-CLIF (Chronic Liver Failure Consortium) JOINT WORKSHOP FROM PATHOGENESIS TO NOVEL THERAPIES**
M. Bernardi, Alma Mater Studiorum - Università di Bologna, Biomecàntica - Policlinico S. Orsola-Malpighi, Italy
A. Gerbes, Germany

**WESTERN VS EASTERN DEFINITIONS - LESSONS FROM THE CANONIC STUDY**
P. Ginés, Spain

**THE NORTH AMERICAN PERSPECTIVE**
P. Kamath, United States

**DISCUSSION**

**ASSESSING PROGNOSIS IN ACUTE-ON-CHRONIC LIVER FAILURE**
R. Jalan, Royal Free Hospital, United Kingdom

**DISCUSSION**

**IS THERE A COMMON PATHOPHYSIOLOGICAL BACKGROUND TO THE VARIOUS MANIFESTATIONS OF ACUTE-ON-CHRONIC LIVER FAILURE?**
R. Moreau, Inserm U 773, Hôpital Beaujon, France

**DISCUSSION**
09:35-10:00  COFFEE BREAK

10:00-10:20  RENAL DYSFUNCTION IN ACUTE-ON-CHRONIC LIVER FAILURE
P. Angeli, University of Padova, Italy

10:20-10:25  DISCUSSION

10:25-10:45  THE CANONIC STUDY: MORE QUESTIONS THAN ANSWERS? FUTURE RESEARCH PERSPECTIVES
V. Arroyo, Spain

10:45-11:00  PANEL DISCUSSION

Joint Workshop, Capital Suite 13

08:00-11:00  EASL-I-PSC-SG (International PSC Study Group) JOINT WORKSHOP
C. Rodrigues, Portugal
G. Hirschfield, University of Birmingham, United Kingdom

08:00-08:30  TARGETING THE GUT-LIVER LYMPHOCYTE AXIS: TREATMENT APPROACHES BASED ON BIOLOGIC INSIGHTS
E. Liaskou, University of Birmingham, United Kingdom

08:30-09:00  CHOLANGIOCYTE BIOLOGY AND BILIARY DISEASE: UNDERSTANDING THE POTENTIAL ROLE OF STEM CELLS IN PSC PATHOGENESIS AND TREATMENT
V. Cardinale, University of Rome, Italy

09:00-09:30  GENETICS OF PSC AND IBD – HOW CAN WE USE GENE ASSOCIATIONS TO JUSTIFY NOVEL IMMUNOMODULATION?
R. Weersma, Germany

09:30-10:00  COFFEE BREAK

10:00-10:30  GUT MICROBIOTA AND BILE ACID HOMEOSTASIS IN PSC – WILL WE EVER TREAT PSC USING ANTIBIOTICS?
J.R. Hov, Norway

10:30-11:00  MOVING FORWARD: DISCUSSIONS ON IMPLICATIONS FOR PATIENTS FROM BASIC RESEARCH
G. Hirschfield, University of Birmingham, United Kingdom
C. Rodrigues, Portugal

Joint Workshop, Capital Suite 5

08:00-11:00  EASL-EPEMED (The European Personalised Medicine Association) JOINT WORKSHOP
M. Albert, Inserm, France
M. Avila, Spain

08:00-08:15  INTRODUCTION
A. Huriez, United Kingdom

08:15-08:30  PERSONALIZED BIOMARKERS FOR SCIENTIFIC DISCOVERY AND DEFINING DISEASE PATHOGENESIS
S. Taylor-Robinson, United Kingdom

08:30-08:45  PERSONALIZED BIOMARKERS USED FOR DIAGNOSIS: AN INDUSTRIAL POINT OF VIEW
P. Leissner, France
Scientific Programme

08:45-09:00  PERSONALIZED BIOMARKERS AND THE STATISTICAL METHODS THAT WILL SUPPORT THEIR IMPLEMENTATION
M. Fontes, , Sweden

09:00-09:15  PERSONALIZED BIOMARKERS AND SPECIAL NEEDS FOR RESOURCE LIMITED COUNTRIES
Y. Yazdan, , France

09:15-10:00  COFFEE BREAK

10:00-10:15  PERSONALIZED BIOMARKERS AS A STRATEGY FOR MANAGING INCREASING COST OF HEALTH CARE
K. Teng, , United States

10:15-11:00  PANEL DISCUSSION / PRIORITIES FOR PERSONALIZED MEDICINE IN FIELD OF HEPATOLOGY; ROLE OF ACADEMIC – INDUSTRIAL PARTNERSHIPS, MORE?
M. Albert, Inserm, France
M. Avila, , Spain

08:00-11:00  EASL-INHSU (The International Network on Hepatitis in Substance Users) JOINT WORKSHOP
A. Aghemo, , Italy
J. Grebely, University of New South Wales, Australia

08:00-08:30  ELIMINATION OF HCV INFECTION AMONG PEOPLE WHO INJECT DRUGS THROUGH TREATMENT AS PREVENTION: FEASIBILITY AND FUTURE REQUIREMENTS
G. Dore, University of New South Wales and St Vincent’s Hospital, Australia

08:30-09:00  TREATMENT OF HCV INFECTION AMONG PEOPLE WITH RECENT OR ACTIVE INJECTING DRUG USE: HOW WILL THE IFN-FREE ERA BE A GAME CHANGER?
G. Foster, Queen Mary University of London, United Kingdom

09:00-09:30  ENHANCING ACCESS TO CARE AND TREATMENT IN THE PRISON SETTING
A. Lloyd, , Australia

09:30-10:00  COFFEE BREAK

10:00-10:20  MANAGEMENT OF ADVANCED LIVER DISEASE IN THE IFN-FREE ERA: IMPLICATIONS FOR THE TREATMENT OF HCV AMONG PEOPLE WHO INJECT DRUGS
M. Puoti, AO Ospedale Niguarda Cà Granda, Italy

10:20-10:40  PATIENT NEEDS IN THE FUTURE OF CARE OF HCV INFECTION AMONG PEOPLE WHO INJECT DRUGS
M. Harris, , United Kingdom

10:40-11:00  PANEL DISCUSSION: WHERE TO FROM HERE? - FUTURE RESEARCH AND CLINICAL PRIORITIES FOR THE MANAGEMENT OF HCV INFECTION AMONG PEOPLE WHO INJECT DRUGS

11:30-13:30  CHRONIC VIRAL HEPATITIS
C. Yurdaydin, University Of Ankara Medical School, Turkey
A. Aghemo, , Italy
C. Sarrazin, J. W. Goethe-University Hospital, Germany
11:30-11:50  MILESTONES IN THE DISCOVERY AND REMAINING CHALLENGES IN HEPATITIS VIRUSES
H. Alter, , United States

11:50-12:00  QUESTIONS CASE PRESENTATION
G. Foster, Queen Mary University of London, United Kingdom

12:00-12:20  DIAGNOSTIC PITFALLS IN CHRONIC VIRAL HEPATITIS: OCCULT HEPATITIS B, HOW TO
EXCLUDE DELTA AND AUTOANTIBODIES RELATED TO HEPATITIS C
F. Negro, Hopital Cantonal Universitaire de Geneve, Switzerland

12:20-12:40  LIVER BIOPSY REMAINS THE GOLD-STANDARD?
T. Roskams, University of Leuven, Belgium

12:40-13:00  NON-INVASIVE TESTS ARE ON A PAR?
M. Friedrich-Rust, J.W. Goethe University Hospital, Germany

13:00-13:20  BIOMARKERS FOR PREDICTION OF TREATMENT RESPONSE IN CHRONIC VIRAL
HEPATITIS B AND C
J. Petersen, IFI Institute at the, Asklepios Klinik St Georg Hamburg, Germany

13:20-13:30  ANSWERS
L. Castéra, Service d’Hépatologie, Hôpital Beaujon, France

Basic Science Seminar, ICC Capital Hall

11:30-13:30  LIVER FIBROSIS: FROM BASIC MECHANISM TO CLINICAL TARGETS
C. Trautwein, , Germany
S. Lotersztajn, , France
M. Pinzani, , United Kingdom

11:30-11:40  IMPACT OF ETIOLOGY ON FIBROSIS
S. Friedman, , United States

11:40-11:50  GENETIC MODELS OF BETA-PDGF RECEPTOR MODULATION IN HEPATIC FIBROSIS,
REGENERATION AND CANCER
P. Kocabayoglu, , Germany

11:50-12:00  DISCUSSION

12:00-12:10  IMPACT OF GENETIC ON FIBROSIS
F. Lammert, Saarland University Hospital, Germany

12:10-12:20  SYSTEMS GENETICS IN RECOMBINANT INBRED MICE
R. Hall, Saarland University Medical Center, Germany

12:20-12:30  DISCUSSION

12:30-12:40  IMPACT OF EPIGENETICS ON FIBROSIS
J. Mann, , United Kingdom

12:40-12:50  THE CLINICAL EVIDENCE OF EPIGENETIC MODIFIERS IN LIVER FIBROSIS
M. Zeybel, Newcastle University, United Kingdom

12:50-13:00  DISCUSSION

13:00-13:10  IMPACT OF BILE ACID RECEPTORS
M. Trauner, Medical University Vienna, Austria

13:10-13:20  LACK OF FXR AMELIORATES SCLEROSING CHOLANGITIS AND BILIARY FIBROSIS, BUT
AGGRAVATES HEPATOCELLULAR INJURY IN MDR2 KNOCKOUT MICE
E. Halilbasic, , Austria
13:20-13:30  DISCUSSION

14:00-15:30  HEPATITIS B
C. Yurdaydin, University Of Ankara Medical School, Turkey
A. Aghemo, , Italy
C. Sarrazin, J. W. Goethe-University Hospital, Germany

14:00-14:10  QUESTIONS CASE PRESENTATION
G. Papatheodoridis, Athens University Medical School, Hippokration Hospital, Greece

14:00-15:30  IMMUNE-MEDIATED MECHANISM
C. Trautwein, , Germany
S. Lotersztajn, , France
M. Pinzani, , United Kingdom

14:00-14:10  ADIPOKINES
F. Marra, Firenze, Italy

14:00-15:30  ACUTE ON CHRONIC HEPATITIS B: NATURAL COURSE AND TREATMENT OPTIONS
Y.-F. Liaw, , Taiwan

14:10-14:25  Hepatitis B Virus: Life Cycle With Old And New Targets For Antiviral Therapy
F. Zoulim, INSERM Unit 871, France

14:10-14:25  QUESTIONS CASE PRESENTATION
G. Papatheodoridis, Athens University Medical School, Hippokration Hospital, Greece

14:10-14:25  Hepatitis B Virus: Life Cycle With Old And New Targets For Antiviral Therapy
F. Zoulim, INSERM Unit 871, France

14:40-15:00  NEW STRATEGIES FOR FINITE TREATMENT
H. Janssen, , Canada

14:40-14:55  CHRONIC HEPATITIS B: WHOM TO TREAT ?
T. Berg, Universitaetsklinik, Germany

14:40-15:00  NEW STRATEGIES FOR FINITE TREATMENT
H. Janssen, , Canada

14:55-15:10  LONG TERM BENEFITS OF TREATMENT
P. Lampertico, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy

14:55-15:10  LONG TERM BENEFITS OF TREATMENT
P. Lampertico, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy

15:00-15:25  MACROPHAGES
J. Iredale, , United Kingdom

15:25-15:30  ANSWERS
G. Dusheiko, , United Kingdom

15:25-15:30  ANSWERS
G. Dusheiko, , United Kingdom

14:00-14:20  Adipokines, Inflammation, And Fibrogenic Signals
A. Cappon, University of Florence, Italy

14:00-14:20  ADIPOKINES, INFLAMMATION, AND FIBROGENIC SIGNALS
A. Cappon, University of Florence, Italy

14:00-15:30  Basic Science Seminar, ICC Capital Hall

14:00-15:30  Basic Science Seminar, ICC Capital Hall

14:20-14:30  DISCUSSION

14:20-14:30  DISCUSSION

14:30-14:40  MACROPHAGES
J. Iredale, , United Kingdom

14:30-14:40  MACROPHAGES
J. Iredale, , United Kingdom

14:40-14:50  FINDING DR JEKYLL AMONGST MANY MR HYDE: IDENTIFYING THE RESTORATIVE HEPATIC MACROPHAGE
P. Ramachandran, , United Kingdom

14:40-14:50  FINDING DR JEKYLL AMONGST MANY MR HYDE: IDENTIFYING THE RESTORATIVE HEPATIC MACROPHAGE
P. Ramachandran, , United Kingdom

14:50-15:00  DISCUSSION

14:50-15:00  DISCUSSION

15:00-15:10  CHEMOKINES
F. Tacke, , Germany

15:00-15:10  CHEMOKINES
F. Tacke, , Germany
15:10-15:20  TRACKING MIGRATION AND FUNCTIONS OF IMMUNE CELL SUBSETS IN INJURED LIVER  
F. Heymann, Germany

15:20-15:30  DISCUSSION

Nurses & Associates Forum, Capital Suite 2-3-4

14:00-15:30  SESSION 1
N. Goutté, Hôpital Beaujon, France  
K. Husi, Switzerland

FOREWORD
K. Husi, Switzerland

14:00-14:30  LIVER TRANSPLANTATION: POINT OF VIEW FROM THE OPERATION ROOM  
F. Van Hove, France

14:30-15:00  DEVELOPMENT OF A CENTRE FOR LIVING DONATION INCORPORATING THE ROLE OF THE NURSE AS MEDICAL DIRECTOR  
D. Lapointe Rudow, United States

15:00-15:30  QUALITY STUDY : INVOLVEMENT OF CNS FOR THE MANAGEMENT OF PATIENTS WITH LIVER DISEASE  
J.M. Morvillers, France

Postgraduate Course, ICC Auditorium

16:00-17:30  HEPATITIS C: CURRENT STANDARD  
C. Yurdaydin, University Of Ankara Medical School, Turkey  
A. Aghemo, Italy  
C. Sarrazin, J. W. Goethe-University Hospital, Germany

16:00-16:10  QUESTIONS CASE PRESENTATION  
A. Mangia, IRCCS 'Casa Sollievo della Sofferenza' Hospital, Italy

16:10-16:25  HEPATITIS C: VIRAL LIFE CYCLE AND TARGETS FOR DIRECT ANTIVIRALS  
D. Moradpour, Switzerland

16:25-16:40  NATURAL HISTORY OF CHRONIC HEPATITIS C: WHO REQUIRES ANTIVIRAL THERAPY?  
A. Alberti, Italy

16:40-17:00  CURRENT TREATMENT OPTIONS FOR HCV GENOTYPE 1: WHAT IS AVAILABLE AND WHO SHOULD RECEIVE TRIPLE THERAPIES NOW?  
C. Hezode, France

17:00-17:20  CURRENT TREATMENT OPTIONS FOR HCV GENOTYPE 2- 6: WHO SHOULD RECEIVE INTERFERON-CONTAINING AND INTERFERON-FREE TREATMENT?  
M. Buti, Hospital Valle Hebron and Ciberehd del Instituto Carlos III, Spain

17:20-17:30  ANSWERS  
O. Weiland, Sweden
Basic Science Seminar, ICC Capital Hall

16:00-17:30 IMMUNE-MEDIATED MECHANISM / CELL BIOLOGY OF FIBROSIS
C. Trautwein, , Germany
S. Lotersztajn, , France
M. Pinzani, , United Kingdom

16:00-16:10 T CELL AND VIRAL INTERACTIONS
M. Maini, University College London, United Kingdom

16:10-16:20 IMMUNE CELL INTERACTIONS IN HEPATITIS B VIRUS-RELATED LIVER FIBROSIS
H. Singh, , United Kingdom

16:20-16:30 DISCUSSION

16:30-16:40 MECHANISMS OF REVERSIBILITY
R. Schwabe, Columbia University, United States

16:40-16:50 TRACKING OF HEPATIC STELLATE CELLS IN FIBROGENESIS AND FIBROSIS REGRESSION
I. Mederacke, , United States

16:50-17:00 DISCUSSION

17:00-17:10 OXIDATIVE STRESS

17:10-17:20 NEW MEDIATORS AND RELATED REDOX MECHANISMS LINKING HYPOXIA AND HYPOXIA-INDUCIBLE FACTORS TO LIVER FIBROGENESIS
S. Cannito, Università di Torino, Italy

17:20-17:30 DISCUSSION

Nurses & Associates Forum, Capital Suite 2-3-4

16:00-17:30 SESSION 2
N. Goutté, Hôpital Beaujon, France
K. Husi, , Switzerland

16:00-16:30 WHAT ARE THE EFFECTS AND SIDE EFFECTS IN NEW HEPATITIS C MEDICATIONS?
M. Lopez Parra, , Spain

16:30-17:00 MANAGEMENT OF HCC TREATMENTS
H. Stoll, , Switzerland

17:00-17:30 HOW TO DEAL WITH HCC PATIENTS: SPECIAL AIMS
CLOSING
N. Goutté, Hôpital Beaujon, France

Major Satellite Symposia, ICC Capital Hall

18:00-19:30 TRANSFORMING HCV MANAGEMENT
G. Foster, Queen Mary University of London, United Kingdom
P. Marcellin, Université Paris-Diderot, France

Welcome
G. Foster, Queen Mary University of London, United Kingdom

HISTORICAL VIEW - WHERE HAVE WE COME FROM?
P. Marcellin, Université Paris-Diderot, France
INVESTIGATOR VIEW - BEING PART OF HISTORY IN THE MAKING
I. Jacobson, Weill Cornell Medical College, United States

Virological View - Understanding the Relevance of Genotype
H. Wedemeyer, Hannover Medical School, Germany

Perspectives on New Candidates for Cure
C. Hezode, , France

Perspectives on Therapy for Challenging Patients
A. Craxi, , Italy

Has the Future Arrived - Perspectives in HCV Tomorrow
G. Foster, Queen Mary University of London, United Kingdom

Major Satellite Symposia, Capital Suite 7-8-9

18:00-19:30 A World Without HCV - Dream or Reality?
M. Manns, Medical School of Hannover, Germany

18:00-18:10 Introduction
M. Manns, Medical School of Hannover, Germany

18:10-18:25 Patient and Policy Focus
C. Gore, , United Kingdom

18:25-18:40 HEOR Expert - Modelling Treatment as Prevention and Burden
N. Martin, University of Bristol, United Kingdom

18:40-18:55 Scottland Model
J. Dillon, , United Kingdom

18:55-19:10 GT4, , An Increasing Concern in Europe
T. Asselah, Hôpital Beaujon, France

19:10-19:25 Screening Programs and Patient Support Partnership
S. Hasurdjiev, ,

19:25-19:30 Synopsis and Conclusion
M. Manns, Medical School of Hannover, Germany
Thursday, 10. April 2014

**Industry Satellite Symposia, ICC Capital Hall**

**07:30-08:30**

**TRANSFORMING HBV PATIENT CARE THROUGH ADVANCES IN UNDERSTANDING**
G. Dusheiko, United Kingdom

**WELCOME AND VIDEO MONTAGE**
G. Dusheiko, United Kingdom

**TRANSFORMING VIEWS ON THE MANAGEMENT OF CHB**
G. Dusheiko, United Kingdom

**TRANSFORMING VIEWS ON DISEASE PROGRESSION AND REJECTION**
T. Asselah, Hôpital Beaujon, France

**TRANSFORMING VIEWS ON DRUG RESISTANCE DEVELOPMENT**
P. Lampertico, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy

**PANEL DISCUSSION AND CONCLUSIONS**
G. Dusheiko, United Kingdom

---

**Industry Satellite Symposia, Capital Suite 7-8-9**

**07:30-08:30**

**THE HIDDEN WORLD OF HEPATIC ENCEPHALOPATHY**
R. Jalan, Royal Free Hospital, United Kingdom

**WELCOME AND OBJECTIVES**
R. Jalan, Royal Free Hospital, United Kingdom

**WHY IS THE FIRST HE EVENT SO IMPORTANT?**
R. Jalan, Royal Free Hospital, United Kingdom

**THE HIDDEN COSTS OF MANAGING HE AND EMERGING EVIDENCE ON THE IMPACT OF HE ON MORTALITY**
M. Hudson, United Kingdom

**THE LOST PATIENT: A QUALITY OF LIFE CASE STUDY**
J.S. Bajaj, Virginia Commonwealth University and McGuire VA Medical Center, United States

**Q/A AND CONCLUSIONS**

---

**Industry Satellite Symposia, Capital Suite 11-12**

**07:30-08:30**

**NALMEFENE - A NEW TREATMENT OPTION IN ALCOHOL DEPENDENCE**

**NALMEFENE - A NEW TREATMENT OPTION IN ALCOHOL DEPENDENCE**
K. Mann, Germany

**DIAGNOSIS OF ALCOHOLIC LIVER DISEASE**
S. Mueller, Department of Internal Medicine, Salem Medical Center and Center for Alcohol Research, University of Heidelberg, Germany
07:30-08:30  **HCV THERAPY: OFF THE SHELF, OR PERSONALISED CARE?**
M. Thursz, United Kingdom

**INTRODUCTION**
M. Thursz, United Kingdom

**PRE-TREATMENT AND ON-THERAPY ASSESSMENTS OF PATIENT RESPONSE: CAN WE FURTHER OPTIMIZE OUTCOMES?**
H. Wedemeyer, Hannover Medical School, Germany

**TREATMENT BEFORE AND AFTER TRANSPLANTATION**
M. Berenguer, Spain

07:30-08:30  **DOES ONE SIZE FIT ALL? HOW DO WE OFFER THE HIGHEST PROBABILITY OF VIROLOGIC CURE IN HCV**

07:30-07:40  **INTRODUCTION**
J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France

07:40-08:20  **OPEN DISCUSSION**
G. Foster, Queen Mary University of London, United Kingdom
F. Poordad, The Texas Liver Institute/University of Texas Health Science Center, United States

08:20-08:30  **FINAL REMARKS AND CONCLUSIONS**
J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France

07:30-08:30  **WHO SYMPOSIUM - LAUNCH OF THE WHO HEPATITIS C TREATMENT GUIDELINES: EVIDENCE, RECOMMENDATIONS AND IMPLICATIONS**
S. Wiktor, World Health Organization (WHO), Switzerland

**WORLD HEALTH ORGANIZATION, GENEVA - SUMMARY OF THE WHO HEPATITIS C TREATMENT GUIDELINES RECOMMENDATION**
S. Wiktor, World Health Organization (WHO), Switzerland

**BURNET INSTITUTE, MELBOURNE - WHAT IS THE EVIDENCE BASE FOR THE WHO HEPATITIS C TREATMENT GUIDELINES RECOMMENDATIONS?**
J. Doyle, Centre for Population Health, Burnet Institute, Australia

**WHAT DO THE WHO HEPATITIS C TREATMENT GUIDELINES MEAN FOR TREATMENT SCALE-UP IN RESOURCE-POOR COUNTRIES?**
I. Andrieux-Meyer, Switzerland

**TREATMENT RECOMMENDATIONS AND ACCESS TO TREATMENT: A PATIENT'S PERSPECTIVE**
C. Gore, United Kingdom
Postgraduate Course, ICC Auditorium

08:30-10:00  **HEPATITIS C: ONGOING AND FUTURE DEVELOPMENTS**
C. Yurdaydin, University Of Ankara Medical School, Turkey
A. Aghemo, , Italy
C. Sarrazin, J. W. Goethe-University Hospital, Germany

08:30-08:40  **QUESTIONS CASE PRESENTATION**
R. Flisiak, Uniwersytet Medyczny, Poland

08:40-08:55  **THE NEW COMERS: TREATMENT OPTIONS TO BE LICENSED IN 2014**
S. Zeuzem, J.W. Goethe University, Germany

08:55-09:10  **IFN-FREE AND RIBAVIRIN FREE REGIMENS**
M. Fried, , United States

09:10-09:25  **WILL VIRAL RESISTANCE BE OF IMPORTANCE?**
J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France

09:25-09:45  **GUIDE FOR CLINICIANS: STRATEGIES TO OPTIMIZE THE NUMBER OF SVRS**
A. Craxi, , Italy

09:45-10:00  **ANSWERS**
P. Marcellin, Université Paris-Diderot, France

Basic Science Seminar, ICC Capital Hall

08:30-10:00  **CELL BIOLOGY OF FIBROSIS**
C. Trautwein, , Germany
S. Lotersztajn, , France
M. Pinzani, , United Kingdom

08:30-08:40  **CELL CYCLE AND HSC**
C. Liedtke, Universitätsklinikum Aachen, Germany

08:40-08:50  **CELL CYCLE REGULATION: NEW INSIGHTS INTO MECHANISM OF LIVER FIBROSIS**
Y. Nevzorova, , Germany

08:50-09:00  **DISCUSSION**

09:00-09:10  **MYOFIBROBLAS**
C. Housset, INSERM & Université Pierre et Maris Curie - Univ Paris 06, France

09:10-09:20  **PORTAL MYOFIBROBLASTS PROMOTE VASCULAR REMODELING UNDERLYING CIRRHOSIS FORMATION THROUGH THE RELEASE OF MICROPARTICLES**
S. Lemoinne, CHU Saint Antoine, France

09:20-09:30  **DISCUSSION**

09:30-09:40  **TARGETING FIBROSIS IN VIVO**
K. Poelstra, University of Groningen, Netherlands

09:40-09:50  **CELL-SPECIFIC DELIVERY OF INTERFERON ALPHA**
A. Adlia, , Netherlands

09:50-10:00  **DISCUSSION**
Scientific Programme

Postgraduate Course, ICC Auditorium

10:30-12:30  SPECIAL POPULATIONS AND CO-INFECTIONS
C. Yurdaydin, University Of Ankara Medical School, Turkey
A. Aghemo, , Italy
C. Sarrazin, J. W. Goethe-University Hospital, Germany

10:30-10:40  QUESTIONS CASE PRESENTATION
M. Cornberg, Medizinische Hochschule Hannover, Germany

10:40-10:55  TREATMENT OF CHB AND CHC IN THE ELDERLY AND PATIENT WITH RENAL IMPAIRMENT
J. Feld, Toronto Western Hospital Liver Centre, Canada

10:55-11:10  TREATMENT OF CHRONIC HEPATITIS C IN THE LIVER TRANSPLANT SETTING
X. Forns, Hospital Clinic, CIBEREHD and IDIBAPS, Spain

11:10-11:30  HBV/HDV: EPIDEMIOLOGY, IFN OR COMBINATION WITH NUCS AND NEW TREATMENT STRATEGIES
H. Wedemeyer, Hannover Medical School, Germany

11:30-11:45  HCV/HDV: VIRAL INTERACTIONS, EFFICACY OF DUAL AND TRIPLE THERAPY AND RISK OF REACTIVATION OF HBV
G. Raimondo, , Italy

11:45-12:05  HCV/HIV: NATURAL HISTORY, LIVER RELATED COMPLICATIONS AND TREATMENT OPTIONS
S. Bhagani, Royal Free London NHS Foundation Trust, United Kingdom

12:05-12:15  ANSWERS
V. Soriano, Hospital Carlos III, Spain

12:15-12:30  SUMMARY AND FUTURE PERSPECTIVES
M. Manns, Medical School of Hannover, Germany
CLOSING REMARKS

Basic Science Seminar, ICC Capital Hall

10:30-12:00  TRANSLATIONAL ASPECTS (ADVANCED LIVER FIBROSIS - NEW CLASSIFICATION, IMAGING, THERAPEUTIC TARGETING)
C. Trautwein, , Germany
S. Lotersztajn, , France
M. Pinzani, , United Kingdom

10:30-10:40  NON INVASIVE DIAGNOSTIC AND PROGNOSTICS
M. Pinzani, , United Kingdom

10:40-10:50  NON-INVASIVE FIBROSIS TESTS: FROM DISCOVERY TO CLINICAL APPLICABILITY
E. Tsochatzis, Royal Free Hospital and UCL Institute of Liver and Digestive Health, United Kingdom

10:50-11:00  DISCUSSION

11:00-11:10  NEED FOR A NOVEL PATHOLOGICAL APPROACH/INTERPRETATION
V. Paradis, Hôpital Beaujon Inserm U773, CRB3, France

11:10-11:20  IMAGING: A STEP TOWARDS FUNCTIONAL PATHOLOGY
M. Ronot, , France

11:20-11:30  DISCUSSION
11:30-12:00 WRAP-UP AND PERSPECTIVES
M. Pinzani, United Kingdom

eposter, Poster Exhibition - ePoster Oral Session Room A

12:15-13:30 HBV
12:15-12:21 INTERFERON ALPHA AND LAMBDA INHIBIT HBV REPLICATION WITH DISTINCT EFFICACY AND KINETICS OF GENE REGULATION IN HUMANIZED MICE
K. Giersch, University Medical Center Hamburg-Eppendorf, Germany

12:21-12:27 COMPARISON OF DIFFERENT IMMUNOREGULATORY PATHWAYS IN HEPATITIS B VIRUS-SPECIFIC CD8+ T-CELL FAILURE
K. Busch, University Hospital Freiburg, Germany

12:27-12:33 TRAINED IMMUNITY IN NEONATES OF HBV-INFECTED MOTHERS
L.W.M. Hong, Singapore Institute for Clinical Sciences, Singapore

12:33-12:39 LONG-TERM OUTCOME OF INACTIVE AND LOW VIREMIC HBEAG NEGATIVE ACTIVE CARRIERS: BENIGN ONE DIRECTION TRANSITION TOWARDS SPONTANEOUS HBSAG CLEARANCE
P. Colombatto, University Hospital Pisa, Italy

12:39-12:45 SEQUENTIAL THERAPY WITH TENOFOVIR AND PEGYLATED INTERFERON-ALPHA 2B VERSUS TENOFOVIR MONOTHERAPY IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB): AN INTERIM ANALYSIS
A. Jindal, ILBS, India

12:45-12:51 SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B

12:51-12:57 TREATMENT CESSATION IS SAFE AND EFFECTIVE AFTER PROLONGED SUPPRESSION WITH NUCLEOSIDES / NUCLEOTIDES IN HBV E-ANTIGEN NEGATIVE, NON-CIRRHOTIC PATIENTS
A. Bonder, Beth Israel Deaconess Medical Center, United States

12:15-13:30 HCC EXPERIMENTAL
12:15-12:21 ADULT HUMAN BILIARY TREE STEM/PROGENITOR CELLS (HBTSCS) ARE EFFICIENTLY REPROGRAMMED TO FUNCTIONAL INSULIN-SECRETING β-PANCREATIC ISLET CELLS BY A NEWLY SYNTHESIZED HUMAN PDX1 PEPTIDE

12:21-12:27 GENE EXPRESSION DURING HEPATOCYTE DIFFERENTIATION DRIVEN BY EPIGENETIC CHANGES: VIA PROMOTERS OR ENHANCERS?

12:27-12:33 P2X4 IMPACTS BILIARY HOMEOSTASIS AND INFLAMMATORY RESPONSE AFTER PARTIAL HEPATECTOMY IN MICE

12:33-12:39 MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION

12:39-12:45 YES-ASSOCIATED PROTEIN (YAP) IS REQUIRED FOR THE CLONAL EXPANSION OF PRENEOPLASTIC HEPATOCYTES AND OVAL CELL PROLIFERATION

12:45-12:51 AXL SIGNALING VIA 14-3-3 ZETA IS CENTRAL FOR THE PROGRESSION OF HEPATOCELLULAR CARCINOMA
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:51-13:06</td>
<td>METABOLIC AND ONCOGENIC CONTRIBUTIONS OF MHC-AP IN OBESITY-ASSOCIATED HEPATOCELLULAR CARCINOMA</td>
</tr>
<tr>
<td>13:06-13:12</td>
<td>PROTEOMIC ANALYSIS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER LIVER RADIOEMBOLIZATION. PRELIMINARY RESULTS</td>
</tr>
</tbody>
</table>

**NASH**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15-13:30</td>
<td>VALIDATION OF FATTY LIVER INDEX FOR IDENTIFYING FATTY LIVER IN A LARGE-SCALE CROSS-SECTIONAL STUDY IN POPULATIONS SEEKING FOR CHECK-UP IN TAIWAN</td>
</tr>
<tr>
<td>12:15-12:21</td>
<td>DO SERUM MARKERS OF CELL INJURY AND DEATH HAVE POTENTIAL TO BECOME MECHANISTIC MARKERS IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)?</td>
</tr>
<tr>
<td>12:27-12:33</td>
<td>ROUX-EN-Y GASTRIC BYPASS ATTENUATES HEPATIC MITOCHONDRIAL DYSFUNCTION IN MICE WITH NONALCOHOLIC STEATOHEPATITIS</td>
</tr>
<tr>
<td>12:33-12:39</td>
<td>QUANTITATIVE AND QUALITATIVE ANALYSIS OF PLASMA FREE FATTY ACIDS AND THEIR IMPACT ON LIVER DAMAGE IN NAFLD PATIENTS</td>
</tr>
<tr>
<td>12:39-12:45</td>
<td>THERAPEUTIC USE OF A CLINICAL STAGE CCR2 INHIBITOR, CCX872, IMPROVES OBESITY ASSOCIATED STEATOHEPATITIS IN MICE</td>
</tr>
<tr>
<td>12:45-12:51</td>
<td>COFFEE DOES NOT PREVENT DEVELOPMENT OF NAFLD BUT MAY DELAY FIBROSIS PROGRESSION: A PROSPECTIVE COHORT STUDY IN THE GENERAL POPULATION</td>
</tr>
</tbody>
</table>

**NON-INVASIVE ASSESSMENT OF LIVER DISEASE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15-13:30</td>
<td>QUANTIFICATION OF FIBROSIS IN CHRONIC HEPATITIS C: PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND ACOUSTIC RADIATION FORCE IMPULSE USING COLLAGEN PROPORTIONATE AREA AS REFERENCE</td>
</tr>
<tr>
<td>12:21-12:27</td>
<td>EVALUATION OF THE PROGNOSTIC VALUE OF NON-INVASIVE LIVER FIBROSIS TESTS TO PREDICT MORTALITY BY TIME-DEPENDENT ROC CURVES</td>
</tr>
<tr>
<td>12:27-12:33</td>
<td>NON-INVASIVE SCORE SYSTEM FOR FIBROSIS (NISF) IN CHRONIC LIVER DISEASE: A NEW MODEL COMBINING BIOCHEMICAL, ELASTOGRAPHIC AND ULTRASOUND DATA</td>
</tr>
<tr>
<td>12:33-12:39</td>
<td>APPLICABILITY (APP) CRITERIA FOR REAL-TIME SHEARWAVE ELASTOGRAPHY (RT-SWE) BY AIXPLORER COMPARED TO TRANSIENT ELASTOGRAPHY (TE) BY FIBROSCAN AND TO FIBROTEST</td>
</tr>
<tr>
<td>12:39-12:45</td>
<td>ENHANCED LIVER FIBROSIS (ELF) TEST PERFORMS BETTER THAN HISTOLOGICAL PARAMETERS IN PREDICTING CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED FIBROSIS DUE TO CHRONIC HEPATITIS C INFECTION</td>
</tr>
<tr>
<td>12:45-12:51</td>
<td>IS THE ELF-SCORE A VALID SUBSTITUTION FOR HVPG TO DETECT CLINICALLY SIGNIFICANT PORTAL HYPERTENSION (CSPH) NON-INVASIVELY?</td>
</tr>
<tr>
<td>12:51-12:57</td>
<td>LOW ACCURACY OF NON-INVASIVE TESTS FOR ASSESSING RESIDUAL CIRRHOSIS IN HEPATITIS C PATIENTS WITH A SUSTAINED VIROLOGICAL RESPONSE</td>
</tr>
</tbody>
</table>
EU Session, Capital Suite 14

12:30-13:30  EU AND IMPACT ON GENERAL HEALTH: SCREENING FOR VIRAL HEPATITIS
D. Prati, Ospedale Alessandro Manzoni, Italy
L. Castéra, Service d’Hépatologie, Hôpital Beaujon, France

12:30-12:50  THE EPIDEMIOLOGY AND BURDEN OF LIVER DISEASES: EMERGING EVIDENCES OVER THE LAST YEARS
M. Thursz, , United Kingdom

12:50-13:10  WHO HEPATITIS C SCREENING, CARE AND TREATMENT GUIDELINES SUMMARY OF RECOMMENDATIONS
S. Wiktor, World Health Organization (WHO), Switzerland

13:10-13:30  ANSWERING THE UNMET NEEDS IN LIVER DISEASES: PROPOSAL FROM THE EASL CAG ON PUBLIC HEALTH
A. Aghemo, , Italy

General Session, ICC Auditorium

13:30-15:30  GENERAL SESSION 1 AND OPENING
M. Peck-Radosavljevic, , Austria
G. Vergani, , United Kingdom

13:30-14:00  WELCOME AND OPENING
G. Vergani, , United Kingdom
M. Peck-Radosavljevic, , Austria

14:00-14:15  SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
S. Zeuzem, J.W. Goethe University, Germany

14:15-14:30  OBETICHOLIC ACID, A FARNESOID-X RECEPTOR AGONIST, REDUCES BACTERIAL TRANSLOCATION AND RESTORES INTESTINAL PERMEABILITY IN A RAT MODEL OF CHOLESTATIC LIVER DISEASE
L. Verbeke, KU Leuven, Belgium

14:30-14:45  ADDING PEGINFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY)
W.P. Brouwer, Willem Pieter Brouwer, Netherlands

14:45-15:00  PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-A-2A PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY
H. Wedemeyer, Hannover Medical School, Germany

15:00-15:15  PRIMARY SCLEROSING CHOLANGITIS FROM A GLOBAL PERSPECTIVE - A MULTICENTER, RETROSPECTIVE, OBSERVATIONAL STUDY OF THE INTERNATIONAL PSC STUDY GROUP
T. Weismüller, University of Bonn, Germany

15:15-15:30  SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE
E. Gane, Auckland Clinical Studies, New Zealand
Parallel Session, ICC Auditorium

**16:00-18:00 HEPATITIS C TREATMENT**

- **16:00-16:15**
  ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0-2: COSMOS STUDY SUBGROUP ANALYSIS
  - M. Sulkowski, Johns Hopkins University, United States

- **16:15-16:30**
  SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY
  - R. Esteban, Vall d'Hebron Hospital, Spain

- **16:30-16:45**
  BOTH CYCLOPHILIN INHIBITORS AND DIRECT-ACTING ANTIVIRALS PREVENT PKR ACTIVATION IN HCV-INFECTED CELLS
  - P. Gallay, The Scripps Research Institute, United States

- **16:45-17:00**
  SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY
  - C. Hezode, France

- **17:00-17:15**
  RETREATMENT OF RELAPSIDERS TO SOFOSBUVIR/ribavirin with sofosbuvir/ledipasvir: complete and rapid virologic suppression by week 4
  - A. Osinusi, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States

- **17:15-17:30**
  RESTORATION OF HCV-SPECIFIC CD8+ T-CELL RESPONSES WITH INTERFERON-FREE TREATMENT OF HEPATITIS C
  - B. Martin, Medical Center, University of Freiburg, Germany

- **17:30-17:45**
  SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN EUROPEAN PATIENTS WHO RELAPSED AFTER PREVIOUS INTERFERON-BASED THERAPY: THE PROMISE TRIAL
  - X. Forns, Hospital Clinic, CIBEREHD and IDIBAPS, Spain

- **17:45-18:00**
  USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV
  - A. Osinusi, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States

Parallel Session, ICC Capital Hall

**16:00-18:00 PORTAL HYPERTENSION: CIRRHOSIS BLEEDING, HEPATORENAL ASCITES**

- **16:00-16:15**
  EFFECTS OF THE FXR AGONIST OBETICHOLIC ACID ON HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN ALCOHOLIC CIRRHOSIS: A PROOF OF CONCEPT PHASE 2A STUDY
  - R. Mookerjee, UCL Institute for Liver & Digestive Health, Royal Free London NHS Foundation Trust and University College London Medical School, United Kingdom
16:15-16:30  **DOES ACUTE HEMODYNAMIC RESPONSE TO CARVEDILOL IN HEPATIC VENOUS PRESSURE GRADIENT PREDICTS MORBIDITY AND MORTALITY IN CIRRHOSIS? PROSPECTIVE STUDY**  
V. Kirnake, Sir Gangaram Hospital, India

16:30-16:45  **IMPACT OF ANTICOAGULANT THERAPY ON UPPER GASTROINTESTINAL BLEEDING (UGI) IN PATIENTS WITH LIVER CIRRHOSIS. RESULTS FROM A RETROSPECTIVE MULTICENTRIC CASE-CONTROL STUDY**  
F. Cerini, IDIBAPS and CIBERehd, University of Barcelona, Spain

16:45-17:00  **RANDOMIZED STUDY OF ENDOSCOPIC BAND LIGATION AND ARGON PLASMA COAGULATION IN THE TREATMENT OF GASTRIC ANTRAL AND FUNDAL VASCULAR ECTASIA**  
M. Elhendawy, Tanta University, Egypt

17:00-17:15  **PROPHYLAXIS OF HEPATIC ENCEPHALOPATHY IN ACUTE VARICEAL BLEED IN PATIENTS WITH CIRRHOSIS: AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL OF LACTULOSE VERSUS RIFAXIMIN**  
S. Maharshi, G B Pant Hospital, India

17:15-17:30  **EARLY, UNEXPECTED LIVER FAILURE AFTER TIPS PLACEMENT IN CIRRHOTIC PATIENTS WITH GOOD LIVER FUNCTION (MELD ≤12): INCIDENCE, OUTCOME AND PROGNOSTIC FACTORS**  
A. Luca, ISMETT, Italy

17:30-17:45  **COVERED TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT SHUNT (TIPS) VERSUS OPTIMIZED MEDICAL TREATMENT OR LIGATION FOR NON-RESPONDERS TO PREVENT VARICEAL REBLEEDING IN CIRRHOSIS. A PRIMARY ANALYSIS**  
T. Sauerbruch, University of Bonn, Germany

17:45-18:00  **TIPS FOR REFRACTORY ASCITES IN CIRRHOSIS: A SINGLE-CENTRE EXPERIENCE USING 8-MM AND 10-MM DIAMETER EXPANDED-POLYTETRAFLUOROETHYLENE (E-PTFE) COVERED STENT**  
A. Luca, ISMETT, Italy

---

**Parallel Session, Capital Suite 7-8-9**

16:00-18:00  **FATTY LIVER DISEASE: CLINICAL AND EXPERIMENTAL**

16:00-16:15  **DECREASED DEVELOPMENT OF DIABETES MELLITUS WITH IMPROVEMENT OF NONALCOHOLIC FATTY LIVER DISEASE: A 10-YEAR JAPANESE COHORT STUDY**  
H. Yamazaki, Teine Keijinkai Hospital, Japan

16:15-16:30  **HEPATOMCYTE SPECIFIC KNOCK-OUT OF AUTOPHAGY INDUCES LIVER INJURY, BUT INHIBITS STEATOSIS AND IMPROVES SERUM LIPIDS IN MICE FED A CONTROL AND METHIONINE CHOLINE DEFICIENT DIET**  
W. Kwanten, University of Antwerp (UA), Belgium

16:30-16:45  **NAFLD IS AN INDEPENDENT PREDICTOR OF EARLY CAROTID ATHEROSCLEROSIS: RESULTS FROM A LARGE TRANSVERSAL STUDY AND LONG-TERM FOLLOW-UP VALIDATION COHORT**  
R. Pais, Hopital Pitie Salpetriere, France

16:45-17:00  **DOES PNPLA3I148M INCREASE LIVER FAT BY EXTRA-HEPATIC MECHANISMS?**  
S. Lallukka, University of Helsinki, Finland
17:00-17:15  **β7-INTEGRINS AND MADCAM-1 PLAY AN OPPOSING ROLE DURING THE DEVELOPMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)**  
H. Drescher, University Hospital Aachen, Germany

17:15-17:30  **ALTERED MITOCHONDRIA IN LIVER-SPECIFIC PROHIBITIN-2 NULL MICE INDUCES HEPATIC DAMAGES ASSOCIATED WITH STEATOSIS AND IMPAIRED GLUCONEOGENESIS**  
J. Martin-Levilain, University of Geneva, University Medical Center, Switzerland

17:30-17:45  **ALCOHOL CONSUMPTION AND HEPATIC STEATOSIS IN THE GENERAL U.S. POPULATION**  
M. Lazo, The Johns Hopkins University School of Medicine, United States

16:00-18:00  **IASL**  
R. Reddy, United States  
M. Thursz, United Kingdom

16:00-16:15  **GENDER DISPARITY AND REAL-LIFE PRACTICE SETTING DIFFERENCES IN ACTUAL TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B MEETING CRITERIA FOR ANTIVIRAL THERAPY**  
L. Kim, Stanford University, United States

16:15-16:30  **PROSPECTIVE EVALUATION OF THE CORRELATION BETWEEN HEMOSTATIC ALTERATIONS AND INCIDENCE OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA**  
A. Zanetto, Padova University Hospital, Italy

16:30-16:45  **SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS**  
M. Lagging, Institute of Biomedicine, University of Gothenburg, Sweden

16:45-17:00  **LIMITED ACCESS TO HCV TESTING AND TREATMENT AMONG INJECTION DRUG USERS ACROSS INDIA**  
S. Solomon, Johns Hopkins University School of Medicine, United States

17:00-17:15  **5-METHYL-1-PHENYL-2-(1H)-PYRIDONE TREATMENT IMPROVES MARKERS OF HEPATIC FUNCTION AND FIBROSIS IN STEATOSIS INDUCED BY HIGH FAT/CARBOHYDRATE DIET**  
J. Macias-Barragán, Universidad de Guadalajara, Mexico

17:15-17:25  **FUNCTIONAL GENOMICS IDENTIFIED A NOVEL PTPRF-MEDIATED GROWTH SUPPRESSION PATHWAY IN HEPATOCARCINOCGENESIS**  
S.-Y. Hsieh, Chang Gung Memorial Hospital and Chang Gung University, Taiwan

T. Matsuda, University of Southern California, United States

17:40-17:55  **PREDICTORS OF TERLIPRESSIN RELATED ADVERSE EFFECTS IN LIVER CIRRHOSIS AND ITS INFLUENCE ON SURVIVAL**  
A. Choudhury, Institute of Liver & Biliary Sciences, India

16:00-18:00  **CLINICAL AND EXPERIMENTAL LIVER TRANSPLANTATION**  
P. Burra, Padova University Hospital, Italy  
T. Wekerle, Austria
16:00-16:15  LONG TERM OUTCOME OF MILD HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A LARGE PROSPECTIVE STUDY
M. Gambato, Liver Unit, Hospital Clínic, IDIBAPS, CiberEHD, Spain

16:15-16:30  TRANSPLANTED PRIMARY MOUSE KUPFFER CELLS ENGRAFT INDEFINITELY WITH RETENTION OF INNATE IMMUNE RESPONSES AND TISSUE REPAIR FUNCTIONS IN LIVER
S. Merlin, University of Piemonte Orientale, Italy

16:45-17:00  SELECTIVE SWITCHING FROM CNI-BASED IMMUNE SUPPRESSION TO SIROLIMUS IMPROVES OUTCOME AFTER LIVER TRANSPLANTATION IN PATIENTS WITH HEPATITIS C VIRUS INFECTION
M. Shah, University of Cambridge, Addenbrooke’s Hospital, United Kingdom

17:00-17:15  CORRECTION OF ACUTE LIVER FAILURE AND PHENYLKETONURIA BY HUMAN AMNION EPITHELIAL STEM CELL THERAPY
S. Strom, Karolinska Institutet, Sweden

17:15-17:30  PERSONALISED TRANSPLANTATION DECISION-MAKING IN ACUTE LIVER FAILURE: DEVELOPMENT AND VALIDATION OF A NOVEL DYNAMIC OUTCOME PREDICTION MODEL FOR PARACETAMOL-INDUCED DISEASE
W. Bernal, Institute of Liver Studies, King’s College Hospital, United Kingdom

17:30-17:45  THE NEW POSSIBILITY OF AUTOLOGOUS HEPATOCYTE TRANSPLANTATION TO PREVENT AND RESCUE FROM LIVER FAILURE AFTER MASSIVE HEPATECTOMY
S. Kita, Kyoto University Hospital, Japan

17:45-18:00  BARCELONA CLINIC LIVER CANCER STAGING AND THE NET BENEFIT OF LIVER RESECTION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTICENTRE, COHORT STUDY
A. Vitale, University Hospital of Padova, Italy

Parallel Session, Capital Suite 14

16:00-18:00  HEPATITIS C EXPERIMENTAL
R. Bartenschlager, Heidelberg University Hospital, Germany
L. Wei, , China

16:00-16:15  PEGYLATED INTERFERON-ALPHA INDUCES SUSTAINED TRANSCRIPTIONAL RESPONSE IN LIVER INFILTRATING IMMUNE CELLS BUT NOT IN HEPATOCYTES IN THE LIVER OF PATIENTS WITH CHRONIC HEPATITIS C
M. Dill, University of Basel, Switzerland

16:15-16:30  VISUALIZATION OF HCV HOST CELL TARGETING IN EX VIVO PERFUSED HUMAN LIVER
X. Cheng, Institute of Virology, Technische Universität München / Helmholtz Zentrum München, Germany

16:30-16:45  SEPTIN 9 BINDS PTDINS4P AND REGULATES LIPID DROPLETS DISTRIBUTION IN HCV INFECTED CELLS
M. Omrane, Inserm, France

16:45-17:00  THE SPECIFIC INFECTIVITY OF HEPATITIS C VIRUS IS REGULATED BY THE CATALYTIC ACTIVITY OF THE LIPID PEROXIDE SCAVENGER GLUTATHIONE PEROXIDASE 4
B. Bartosch, , France

17:00-17:15  THE RIBOSOMAL PROTEIN RACK1 IS REQUIRED FOR IRES-MEDIATED TRANSLATION OF HEPATITIS C VIRUS INDEPENDENTLY OF MIR122
M.L. Hafirassou, Inserm U 748, France

17:15-17:30  APOLIPOPROTEIN E MEDIATES HCV ESCAPE FROM HOST NEUTRALIZING ANTIBODIES
D. Felmlee, University of Strasbourg, France
17:30-17:45  **SERUM LEVELS OF THE ENDOGENOUS HCV ENTRY INHIBITOR OXIDIZED LDL (OXLDL) PREDICT SVR FOLLOWING INTERFERON-BASED THERAPY OF CHRONIC HEPATITIS C**  
S. Westhaus, Hannover Medical School, Germany

17:45-18:00  **SPONTANEOUS RESOLUTION OF HEPATITIS C VIRUS INFECTION IS ASSOCIATED WITH THE PRESENCE OF ANTI-RECEPTOR ANTIBODIES IN A COHORT OF SINGLE-SOURCE OUTBREAK**  
R. Tawar, INSERM U 1110, France

**Major Satellite Symposia, ICC Auditorium**

18:30-20:00  **DIVERSITY AND DECISIONS IN THE ERA OF NEW DAAS: EXPERT CLINICAL GUIDANCE**  
M. Manns, Medical School of Hannover, Germany

18:30-18:35  **INTRODUCTIONS AND WELCOME**  
M. Manns, Medical School of Hannover, Germany

18:35-18:45  **DEFINING THE GLOBAL HEPATITIS C PROBLEM**  
J. Dillon, United Kingdom

18:45-19:05  **WHAT CAN WE EXPECT FROM THE NEW GENERATION OF DAAS?**  
M. Manns, Medical School of Hannover, Germany

19:05-19:15  **VIEW FROM THE CLINIC: A SERIES OF CASE STUDIES**

19:15-19:25  **THE CIRRHOTIC GENOTYPE 1 PATIENT**  
A. Brown, United Kingdom

19:25-19:40  **ADDRESSING UNMET NEEDS IN GENOTYPE 4**  
T. Asselah, Hôpital Beaujon, France

19:40-19:55  **PREDICTORS OF RESPONSE**  
C. Sarrazin, J. W. Goethe-University Hospital, Germany

19:55-20:00  **CLOSE**  
M. Manns, Medical School of Hannover, Germany

**Major Satellite Symposia, ICC Capital Hall**

18:30-20:00  **MULTIPLE ROUTES: GETTING ON TRACK TO SUCCESSFUL TREATMENT IN HEPATITIS C**  
R. Flisiak, Uniwersytet Medyczny, Poland

**THE JOURNEY AHEAD: INTRODUCTION**  
R. Flisiak, Uniwersytet Medyczny, Poland

**EMERGING DATA FOR NEW THERAPEUTIC OPTIONS**  
S. Zeuzem, J.W. Goethe University, Germany

**THE IMPACT OF THE CHANGING TREATMENT LANDSCAPE AND THE DIFFICULTIES ACCESSING THESE TREATMENTS**  
R. Bruno, Italy
WHAT ARE YOUR OPTIONS FOR HCV TREATMENT TODAY?
M. Shiffman, ,

QUESTION AND ANSWER SESSION
R. Flisiak, Uniwersytet Medyczny, Poland

CONTINUING THE JOURNEY: NEXT STOP?
R. Flisiak, Uniwersytet Medyczny, Poland

Sonography course, Capital Suite 10

18:30-20:00  SONOGRAPHY COURSE FOR BEGINNERS
R. de Knegt, , Netherlands
M. Gebel, Center for Internal Medicine, Hannover Medical School, Germany

TUTORS
R. de Knegt, , Netherlands
M. Gebel, Center for Internal Medicine, Hannover Medical School, Germany
C. Terkamp, , Germany
A. Potthoff, , Germany
P. Taimr, , Netherlands
D. Sprengers, Academic Medical Center, University of Amsterdam, Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-08:30</td>
<td><strong>CARDIOPULMONARY COMPLICATIONS IN CIRRHOSIS</strong></td>
<td>V. Fuhrmann, Medical University Vienna, Austria</td>
<td>Capital Suite 7-8-9</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td><strong>HEPATIC ENCEPHALOPATHY</strong></td>
<td>S. Montagnese, University of Padua, Italy</td>
<td>Capital Suite 11-12</td>
</tr>
<tr>
<td>07:30-07:35</td>
<td><strong>WELCOME AND INTRODUCTION</strong></td>
<td>H. Vlstrup, Aarhus University Hospital, Denmark</td>
<td></td>
</tr>
<tr>
<td>07:35-07:55</td>
<td><strong>HE OR WHAT ELSE?</strong></td>
<td>S. Montagnese, University of Padua, Italy</td>
<td></td>
</tr>
<tr>
<td>07:55-08:07</td>
<td><strong>COGNITIVE NETWORKS ETC IN PBC</strong></td>
<td>V. Mosher, University of Calgary, Canada</td>
<td></td>
</tr>
<tr>
<td>08:07-08:19</td>
<td><strong>NEURO DISORDERS DURING HEV ETC</strong></td>
<td>H. Blasco Perrin, CHU Toulouse Purpan, France</td>
<td></td>
</tr>
<tr>
<td>08:19-08:29</td>
<td><strong>HOW TO PRESENT A CASE OF HE</strong></td>
<td>H. Vlstrup, Aarhus University Hospital, Denmark</td>
<td></td>
</tr>
<tr>
<td>07:30-08:30</td>
<td><strong>LIVER DISEASE IN PREGNANCY</strong></td>
<td>R. Oren, A.E. Kremer, Israel</td>
<td>Capital Suite 2-3-4</td>
</tr>
<tr>
<td>07:30-08:30</td>
<td><strong>PREGNANCY AND PRIMARY BILIARY CIRRHOSIS: A CASE-CONTROL STUDY</strong></td>
<td>I. Franceschet, University of Padova, Italy</td>
<td></td>
</tr>
<tr>
<td>07:30-08:30</td>
<td><strong>NAFLD – PATHOGENESIS AND MANAGEMENT</strong></td>
<td>V. Ratziu, Hopital Pitié Salpêtrière, France</td>
<td></td>
</tr>
<tr>
<td>07:30-08:00</td>
<td><strong>VITAMIN E MODULATES INFLAMMATION AND LIPID PEROXIDATION THROUGH CERAMIDE AND EICOSANOID PATHWAYS - NOVEL LIPIDOMIC INSIGHTS INTO POTENTIAL MECHANISMS OF ACTION OF VITAMIN E IN NASH</strong></td>
<td>P. Puri, Virginia Commonwealth University School of Medicine, United States</td>
<td></td>
</tr>
<tr>
<td>08:00-08:30</td>
<td><strong>THERAPEUTIC USE OF A CLINICAL STAGE CCR2 INHIBITOR, CCX872, IMPROVES OBESITY ASSOCIATED STEATOHEPATITIS IN MICE</strong></td>
<td>R. Parker, Centre for Liver Research, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
07:30-08:30 **Evolving Mechanisms and Therapies in Hepatic Fibrosis**  
V. Lukacs-Kornek, Germany  
M. Pinzani, United Kingdom

07:30-08:00 **Promotion of Liver Injury and Fibrosis by the Liver-Derived Plasma Protein Histidine-Rich Glycoprotein is Based on Polarizing Hepatic Macrophages Towards the Inflammatory M1 Phenotype**  
M. Bartneck, Medical Faculty, RWTH University, Germany

08:00-08:30 **Integrative MicroRNA and Genomic Analysis Identifies miR-21, miR-100 and miR-192 as New Regulatory Elements of Hepatic Stellate Cell Activation**  
M. Coll, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain

07:30-08:30 **NAFLD and Hepatocellular Carcinoma**  
J. Idle, Switzerland  
V. Paradis, Hôpital Beaujon Inserm U773, CRB3, France

07:30-08:00 **Visceral Adipose Tissue Affects Liver Injury of NAFLD and NASH Patients**  
M. Schlattjan, University Hospital, University Duisburg-Essen, Germany

08:00-08:30 **Microparticles from Hypertrophied Adipocytes or Obese Mouse Activate Monocytes and Macrophages Resulting in Contribution of Liver Inflammation**  
A. Eguchi, University of California San Diego, United States

07:30-08:30 **Difficult to Treat Patients with Chronic Hepatitis B: Do They Still Exist?**  
F. van Bommel, Germany  
M. Sonneveld, Erasmus MC University Medical Center, Netherlands

07:30-08:00 **Sequential Therapy with Tenofovir and Pegylated Interferon-alpha 2b Versus Tenofovir Monotherapy in HBeAg Positive Chronic Hepatitis B (CHB): An Interim Analysis**  
A. Jindal, ILBS, India

08:00-08:30 **High Virological Relapse Rate After Nucleos(t)ide Analogue Discontinuation in Chronic Hepatitis B**

07:30-08:30 **HCV Treatment in Special Populations**  
S. Pol, Hopital Cochin, France  
D.J. Mutimer, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, United Kingdom

07:30-08:30 **Interferon Lambda 4 (IFNL4) Polymorphism Predicts Response to Hepatitis C Treatment After Liver Transplantation**  
C. Fernández-Carrillo, Hospital Clinic, IDIBAPS, CIBERehd, Spain
Early Morning Workshop, Capital Suite 6

07:30-08:30 **TREATMENT OF VIRAL HEPATITIS IN PATIENTS WITH HCC**
M. Colombo, Fondazione IRCCS Maggiore Hospital, University of Milan, Italy
M. Reig, Hospital Clinic, Spain

07:30-08:30 **TREATMENT OF HCV IN PREVIOUS NON RESPONDERS**
C. Moreno, Erasmus Hospital, Université Libre de Bruxelles (ULB), Belgium
M. Gschwantler, Austria

07:30-08:30 **TELAPREVIR-BASED TRIPLE THERAPY IN PATIENTS WITH MODERATE FIBROSIS. SPANISH MULTICENTRE STUDY IN CLINICAL PRACTICE**
J. Cabezas Gonzalez, Hospital Universitario Marques de Valdecilla, Spain

Early Morning Workshop, Capital Suite 5

07:30-08:30 **LIVER TRANSPLANTATION IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS**
P. Maturin, France
J.G. O'Grady, Kings College Hospital, United Kingdom

07:30-08:00 **LIVER TRANSPLANTATION OUTCOMES IN PATIENTS WITH PORTOPULMONARY HYPERTENSION IN THE UNITED STATES: 2006-2013**
M. Fallon, University of Texas Health Science Center, United States

08:00-08:30 **LIVER DAMAGE DETERMINES THE GENE EXPRESSION PROFILE OF LIVER PROGENITOR CELLS AND THEIR CONTRIBUTION TO HEPATIC REGENERATION**
D. Rodrigo-Torres, Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain

Early Morning Workshop, London Suite 1

07:30-08:30 **UPDATE ON THE NEW DRUGS FOR HCC**
C. Verslype, Belgium
F. Piscaglia, S.Orsola-Malpighi University Hospital, Italy

07:30-08:00 **HUMAN CHOLANGIOCARCINOMA (CCA) AND CCA CANCER STEM CELLS (CSCS) ARE HIGHLY SENSITIVE TO THE ANTIPROLIFERATIVE EFFECTS OF PI3-K INHIBITORS**
A. Fraveto, Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy

08:00-08:30 **TEMPORAL DYNAMICS AND THERAPEUTIC POTENTIAL OF THE UNFOLDED PROTEIN RESPONSE IN HEPATOCELLULAR CARCINOMA**
Y.-P. Vandewynckel, Ghent University Hospital, Belgium

Early Morning Workshop, London Suite 2

07:30-08:30 **HOW TO DIAGNOSE SMALL HEPATOCELLULAR CARCINOMAS**
V. Vigrain, France
D. Strobel, Germany
08:30-10:30 GENERAL SESSION 2 & AWARDS 1

08:30-08:45 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR OF HCV GENOTYPE-1 INFECTED PATIENTS WHO FAILED PRIOR THERAPY WITH PEGINTERFERON + RIBAVIRIN PLUS 1 OR 2 ADDITIONAL DIRECT-ACTING ANTIVIRAL AGENTS
S. Pol, Hopital Cochin, France

08:45-09:00 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY
K. Kowdley, Virginia Mason Medical Center, United States

09:00-09:15 EARLY CARDIOVASCULAR DISEASE MORTALITY AFTER LIVER TRANSPLANTATION - IS NONALCOHOLIC STEATOHEPATITIS (NASH) TO BLAME?
L. VanWagner, Northwestern University Feinberg School of Medicine, United States

09:15-09:45 AWARD CEREMONY I

09:45-10:00 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION
C. Hezode, France

10:00-10:15 MICE WITH AXIN-1 LIVER SPECIFIC DELETION DEVELOP HEPATOCELLULAR CARCINOMAS WITHOUT BETA-CATENIN ACTIVATION
H. Gilgenkrantz, INSERM U 1016, CNRS UMR 8104, University Paris Descartes, France

10:15-10:30 SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAÏVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
J. Feld, Toronto Western Hospital Liver Centre, Canada

10:30-11:00 HORMONES AND OBESITY

11:00-11:15 KEYNOTE SPEAKER
S. Bloom, United Kingdom

11:30-12:30 VIRAL HEPATITIS

11:30-12:00 ANTIVIRAL THERAPY OF HEPATITIS C IN CIRRHOTIC PATIENTS AWAITING TRANSPLANTATION AND IN LIVER TRANSPLANT RECIPIENTS: INDICATIONS AND PRACTICAL MANAGEMENT
M.-C. Londoño, Hospital Clínico, Spain
R. Miquel, Spain

12:00-12:30 HEPATITIS B REACTIVATION IN AN INACTIVE HBV CARRIER: NATURAL HISTORY AND CLINICAL OUTCOMES
S. Lens, Hospital Clinic, IDIBAPS, CIBEREHD, Spain
R. Miquel, Spain
11:30-12:30  COMPLICATIONS OF CIRRHOSIS - BEYOND EVIDENCE
R. Jalan, Royal Free Hospital, United Kingdom

11:30-11:50  HEPATIC ENCEPHALOPATHY: THE MORE THINGS CHANGE THE MORE THEY REMAIN THE SAME
D. Patch, , United Kingdom
P. Dhillon, , United Kingdom
D. Yu, , United Kingdom
J. Macnaughtan, , United Kingdom

11:50-12:10  REFRACTORY ASCITES: TAPS, TIPS AND PUMPS
D. Patch, , United Kingdom
P. Dhillon, , United Kingdom
D. Yu, , United Kingdom
J. Macnaughtan, , United Kingdom

12:10-12:30  RESCUE FROM ACUTE ON CHRONIC LIVER FAILURE
D. Patch, , United Kingdom
P. Dhillon, , United Kingdom
D. Yu, , United Kingdom
J. Macnaughtan, , United Kingdom

11:30-12:30  LIVER TUMOURS
C. Toso, , Switzerland

11:30-12:00  CASE 1: HEPATOCELLULAR ADENOMA
L. Rubbia-Brandt, , Switzerland
L. Spahr, , Switzerland

12:00-12:30  CASE 2: HEPATOCELLULAR CARCINOMA
P. Majno, , Switzerland

11:30-12:30  METABOLIC LIVER DISEASE
P. Ferenci, Medical University of Vienna, Austria

11:30-11:50  CASE 1: DIABETIC WOMEN WITH ABNORMAL LFT’S
H. Hofer, Medical University of Vienna, Austria

11:50-12:10  CASE 2: PATIENT WITH LOW CAERULOPLASMIN BUT NORMAL HEPATIC COPPER CONTENT
H. Zoller, , Austria

12:10-12:30  PATHOLOGIST
K. Lackner, , Austria

11:30-12:30  YI SEMINAR 2014: LIVER DISEASE IN PREGNANCY
F. Lammert, Saarland University Hospital, Germany
R. Liberal, King ´s College London School of Medicine, King ´s College Hospital, United Kingdom
11:30-11:50  CHOLESTASIS - MECHANISMS AND RELEVANCE TO PREGNANCY
C. Williamson, United Kingdom

11:50-12:10  HYPERTENSION INDUCED LIVER DISEASE IN PREGNANCY - PATHOGENESIS AND PRESENTATION
J. Bernuau, France

12:10-12:30  VIRAL HEPATITIS IN PREGNANCY
R. Tur-Kaspa, Israel

11:30-12:30  THE ENCODE PROJECT
R. Guigó, Spain

11:30-11:50  OVERVIEW OF THE ENCODE PROJECT
R. Guigó, Spain

11:50-12:10  DATA ANALYSIS IN THE ENCODE PROJECT
I. Dunham, United Kingdom

12:10-12:30  THE GENECODE SUBPROJECT: ANNOTATION OF THE HUMAN GENOME
T. Hubbard, United Kingdom

12:30-14:00  HCV
M. Lagging, Institute of Biomedicine, University of Gothenburg, Sweden

12:30-12:36  NK-CELL FREQUENCY AND PHENOTYPE AFFECT THE OUTCOME OF ACUTE HEPATITIS VIRUS C INFECTION

12:36-12:42  RIBAVIRIN PRETREATMENT IMPROVES THE IFN-γ RESPONSE OF NATURAL KILLER CELLS TO IFN-BASED THERAPY OF HEPATITIS C VIRUS INFECTION

12:42-12:48  HEPATITIS C VIRUS COMPARTMENTALISATION: UNRAVELLING GENETIC COMPLEXITY WITHIN THE LIVER

12:48-12:54  REDUCTION OF MIR-122 IN IFNL3 CT+TT CARRIERS AND DURING PROGRESSION OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C

12:54-13:00  LONG TERM FOLLOW-UP OF PATIENTS TREATED WITH SOFOSBUVIR IN THE FISSION, POSITRON, FUSION AND NEUTRINO PHASE 3 STUDIES

13:00-13:06  EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR+RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL

13:06-13:12  LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/- RIBAVIRIN

12:30-14:00  COMPLICATION OF CIRRHOSIS
M. Senzolo, Italy
12:30-12:36  VENOUS THROMBOEMBOLISM AND RISK OF CANCER IN PATIENTS WITH LIVER DISEASE: A POPULATION-BASED COHORT STUDY

12:36-12:42  RESISTANCE TO THROMBOMODULIN IS ASSOCIATED WITH DE NOVO PORTAL VEIN THROMBOSIS AND COULD BE A MODIFIABLE FACTOR TO IMPROVE PROGNOSIS IN PATIENTS WITH CIRRHOSIS

12:42-12:48  SHORT-TERM (28-DAY) CLINICAL COURSE AND TRANSPLANT-FREE MORTALITY IN ACUTE ON CHRONIC LIVER FAILURE (ACLF); EVIDENCE FOR REVERSIBILITY OF ACLF (A STUDY FROM THE CANONIC DATABASE)

12:48-12:54  FIBROSIS PROGRESSION IN A NON-INFLAMMATORY SMALL ANIMAL MODEL OF LIVER CONGESTION

12:54-13:00  COMMENSAL BACTERIA DRIVES THE EXPANSION OF PROINFLAMMATORY T-LYMPHOCYTES IN THE SMALL INTESTINAL MUCOSA AND WORSENS THE EPITHELIAL BARRIER FUNCTION IN CCL4 CIRRHTIC RATS WITH ASCITIS

13:00-13:06  BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: RISK FACTORS AND RATE OF FAILURE OF THE EMPIRICAL ANTIBIOTIC THERAPY

13:06-13:12  DOES THE GUT MICROBIOTA MODULATE THE INFLAMMATORY STATE IN CIRRHOTIC HOST?

12:30-14:00  METABOLIC LIVER DISEASE (NOT NAFLD)
R. Bruha, Charles University in Prague, 1st Faculty of Medicine, Czech Republic

12:30-12:36  ACTIVATION OF PPAR-γ SIGNALING AS A NOVEL TARGET TO LIMIT NFKB-DEPENDENT INFLAMMATION IN CYSTIC FIBROSIS BILIARY EPITHELIUM

12:36-12:42  IDENTIFYING INCIDENCE OF INHERITED METABOLIC DISORDERS IN PATIENTS WITH INFANTILE LIVER DISEASE

12:42-12:48  PHLEBOTOMY FREQUENCY REDUCED BY PROTON PUMP INHIBITORS IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS

12:48-12:54  THE ROLE OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) IN CHOLESTASIS UND BILE ACID (BA) SYNTHESIS

12:54-13:00  TNFα CLEAVING ENZYME (TACE/ADAM 17) IS AN IMPORTANT DRIVER OF CHOLESTASIS-ASSOCIATED LIVER INJURY AND SICKNESS BEHAVIOR DEVELOPMENT

13:00-13:06  ENHANCED LIVER FIBROSIS SCORE PREDICTS TRANSPLANT-FREE SURVIVAL IN PSC INDEPENDENTLY OF THE MAYO RISK SCORE

13:06-13:12  APOPTOSIS INDUCED BY BILIRUBIN AND LITHOCHOLIC ACID IN HUMAN OSTEOBLASTS IS NEUTRALIZED BY URSDODEOXCHOLIC ACID

12:30-14:00  ALCOHOL
F. Stickel, University of Berne, Switzerland

12:30-12:36  ALCOHOLIC LIVER DISEASE IN DENMARK 2006-2011: A POPULATION-BASED DESCRIPTIVE STUDY

12:36-12:42  MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS

12:42-12:48  A COMMON POLYMORPHISM IN THE NCAN GENE IS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN ALCOHOLIC LIVER DISEASE
12:48-12:54 TRANSLATIONAL STUDY IDENTIFIES NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A POTENTIAL MEDIATOR OF LIVER INJURY AND FIBROGENESIS IN ALCOHOLIC HEPATITIS

12:54-13:00 BACLOFENE LEADS TO ALCOHOL CONSUMPTION REDUCTION AND HEPATIC IMPROVEMENT IN CIRRHOTIC PATIENTS

13:00-13:06 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH-LATIN-AMERICAN DILI REGISTRY

13:06-13:12 AMIODARONE HEPATOTOXICITY IS MEDIATED VIA INDUCTION OF STATOSIS, ER STRESS AND MTOR ACTIVATION IN-VIVO AND IN-VITRO

Symposia, ICC Auditorium

14:00-15:30 EASL – IASL JOINT SYMPOSIUM: DRUG INDUCED LIVER DISEASE: GLOBAL PERSPECTIVE
M. Mondelli, Fondazione IRCCS Policlinico San Matteo, Italy
F. Lammert, Saarland University Hospital, Germany

14:00-14:15 GLOBAL BURDEN OF DRUG INDUCED LIVER DISEASE
G. Aithal, Nottingham University Hospitals NHS Trust and University of Nottingham, United Kingdom

14:15-14:30 DILI: CHALLENGES WITH CAUSALITY ASSESSMENT
R.J. Andrade, Unidad de Gestión Clínica de Enfermedades Digestivas, Servicio de Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga. CIBERehd, Spain

14:30-14:45 DILI IN THE WEST: CURRENT STATUS
B. Fontana, , United States

14:45-15:00 DILI IN THE EAST
S.G. Lim, National University Health System, Singapore

15:00-15:15 HERBAL HEPATOTOXICITY: IS IT A PROBLEM AND UNDER RECOGNIZED
D. Larrey, , France

15:15-15:30 DISCUSSION

Symposia, ICC Capital Hall

14:00-15:30 EASL CLINICAL SYMPOSIUM: ACUTE KIDNEY INJURY IN LIVER DISEASE
P. Angeli, University of Padova, Italy

14:00-14:20 PATHOPHYSIOLOGY AND DIFFERENT PHENOTYPES OF AKI IN PATIENTS WITH CIRRHOSIS
M. Bernardi, Alma Mater Studiorum - Università di Bologna, Semeiotica Medica - Policlinico S. Orsola-Malpighi, Italy

14:20-14:40 AKIN CRITERIA VERSUS CONVENTIONAL CRITERIA FOR THE ASSESSMENT OF AKI IN PATIENTS WITH CIRRHOSIS
P. Ginés, , Spain

14:40-14:55 THE RELEVANCE OF AKI IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE
R. Moreau, Inserm U 773, Hôpital Beaujon, France
14:55-15:10 MANAGEMENT OF AKI IN PATIENTS WITH CIRRHOSIS: TOWARDS AN UNIFYING PROPOSAL
P. Angeli, University of Padova, Italy

15:10-15:25 DISCUSSION

14:00-15:30 EASL CLINICAL SYMPOSIUM: DIAGNOSIS AND ASSESSMENT IN LIVER CANCER
M. Woerns, Germany

14:00-14:30 WHAT DO WE NEED FOR PERSONALIZED MEDICINE IN SURGICAL PROCEDURES?
C. Toso, Switzerland

14:30-15:00 PATIENT SELECTION AND TREATMENT RESPONSE IN TRANSARTERIAL APPROACHES
W. Sieghart, Medical University of Vienna, Austria

15:00-15:30 FROM BIOPSY TO CLINICAL TRIAL DESIGN IN THE ERA OF TARGETED THERAPY
A. Villanueva, United Kingdom

14:00-15:30 EASL BASIC SYMPOSIUM: LIPOTOXICITY AND FATTY LIVER DISEASE
J. Fernandez-Checa, Spain

14:00-14:30 LIPID AND STRESS SIGNALING IN NAFLD
J. Maher, United States

14:30-15:00 CHOLESTEROL AND THE TRANSITION FROM STEATOSIS TO STEATOHEPATITIS
C. Garcia Ruiz, Spain

15:00-15:30 ROLE OF CERAMIDE IN HEPATOSTEATOSIS AND OXIDATIVE STRESS
Y. Pewzner-Jung, Israel

14:00-15:30 EASL TRANSLATIONAL WORKSHOP: NON-CODING RNA IN LIVER DISEASE
M. Negrini, Italy

14:00-14:15 INTRODUCTION
M. Negrini, Italy

14:15-14:40 EFFECTS OF MIRNA DEREGLATION IN HCC: ABNORMAL MIRNA IN CANCER PATHWAY
L. Gramantieri, Italy

14:40-15:05 MIR-122 AS A TUMOR SUPPRESSOR IN HEPATOCARCINOGENESIS
M.B. Zeisel, France

15:05-15:30 GENERAL VIEW AND FUNCTION OF LNCRNAS: LONG NON-CODING RNAS (LNCRNA), MIRNA REGULATION
C. Braconi, University of Glasgow, United Kingdom
**Parallel Session, ICC Auditorium**

16:00-18:00  **HEPATITIS C: NEW ANTIVIRAL**

R. Esteban-Mur, Spain
G. Dusheiko, United Kingdom

16:00-16:15  **EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY**

E. Lawitz, Texas Liver Institute, University of Texas Health Science Center, United States

16:15-16:30  **SOFOBUVIR COMPASSIONATE USE PROGRAM FOR PATIENTS WITH SEVERE RECURRENT HEPATITIS C INCLUDING FIBROSING CHOLESTATIC HEPATITIS FOLLOWING LIVER TRANSPLANTATION**

X. Forns, Hospital Clinic, CIBEREHD and IDIBAPS, Spain

16:30-16:45  **EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY**

M. Sulkowski, Johns Hopkins University, United States

16:45-17:00  **EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION**

F. McPhee, Bristol-Myers Squibb, United States

17:00-17:15  **HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVID, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN**

J. Lalezari, Quest Clinical Research, United States

17:15-17:30  **SOFOBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS**

G. Foster, Queen Mary University of London, United Kingdom

17:30-17:45  **COMORBID CONDITIONS ASSOCIATED WITH DECISION-MAKING REGARDING TREATING OR NOT TREATING CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION**

L. Nyberg, Kaiser Permanente, United States

17:45-18:00  **SOFOBUVIR AND RIBAVIRIN FOR THE TREATMENT CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY**

N. Afdhal, Beth Israel Deaconess Medical Center, United States

**Parallel Session, ICC Capital Hall**

16:00-18:00  **COMPLICATIONS OF CIRRHOSIS**

T. Sauerbruch, University of Bonn, Germany

16:00-16:15  **ALBUMIN INFUSION FOR BACTERIAL INFECTIONS OTHER THAN SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC PATIENTS: A MULTICENTER RANDOMIZED CONTROLLED STUDY (ALB-CIRINF STUDY)**

T. Thévenot, Hôpital Minjoz, France

16:15-16:30  **LIFETOUCH®: A NOVEL REMOTE MONITORING DEVICE TO IDENTIFY PATIENTS WITH ADVANCED CIRRHOSIS MOST AT RISK OF DECOMPENSATION - A PROOF OF CONCEPT STUDY**

D. Chatterjee, UCL Institute for Liver & Digestive Health, Royal Free London NHS Foundation Trust and University College London Medical School, United Kingdom
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30-16:45</td>
<td>MASSIVE HEPATIC NECROSIS IS A CRITICAL PATHOLOGICAL FEATURE TO DISTINGUISH ACUTE-ON-CHRONIC LIVER FAILURE AS A SEPARATE ENTITY FROM CIRRHOTIC PATIENTS WITH ACUTE DECOMPENSATION</td>
<td>H. Li, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, China</td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>PHASE 1-2 CLINICAL TRIAL IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS TREATED WITH BONE-MARROW DERIVED ENDOTELIAL PROGENITOR CELLS: PRELIMINARY SAFETY AND EFFICACY ANALYSIS</td>
<td>D. D'Avola, Clinica Universidad de Navarra, Spain</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>PROGNOSTIC VALUE OF MUSCLE ATROPHY IN CIRRHOSIS USING PSOAS MUSCLE THICKNESS ON COMPUTED TOMOGRAPHY</td>
<td>C. Francoz, Hospital Beaujon, France</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) IS A STRONG PREDICTOR OF SHORT-TERM OUTCOME IN PATIENTS WITH ACUTE DECOMPENSATION OF CIRRHOSIS. RELATIONSHIP WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)</td>
<td>X. Ariza, Liver Unit, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>RELEVANCE OF LIVER FUNCTION TESTS AS PROGNOSTIC MARKERS IN CHRONIC PRECAPILLARY PULMONARY HYPERTENSION</td>
<td>K. Grotemeyer, Saarland University Hospital, Germany</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>THE OCCURRENCE OF SPONTANEOUS BACTERIAL PERITONITIS CLOSES THE THERAPEUTIC WINDOW OF OPPORTUNITY FOR NON-SELECTIVE BETA BLOCKER TREATMENT IN CIRRHOTIC PATIENTS WITH ASCITES</td>
<td>M. Mandorfer, Medical University of Vienna, Austria</td>
</tr>
</tbody>
</table>

Parallel Session, Capital Suite 7-8-9

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-17:00</td>
<td>NON INVASIVE</td>
<td>A. Berzigotti, Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBERehd, Spain, M. Pinzani, United Kingdom</td>
</tr>
<tr>
<td>16:00-16:15</td>
<td>PROGNOSTIC MODELS FOR MORTALITY USING THE SUCCESSIVE VALUES OF NON-INVASIVE FIBROSIS TESTS IN PATIENTS WITH CHRONIC LIVER DISEASE</td>
<td>S. Bertrais, University of Angers, France</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>PROSPECTIVE COMPARISON OF LIVER AND SPLEEN STIFFNESS AND COMPOSITE SCORES, USING SUPERSONIC-SHEAR-IMAGING OR TRANSIENT ELASTOGRAPHY, FOR DETECTING CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN PATIENTS WITH CIRRHOSIS</td>
<td>L. Elkrief, Service d'Hépatologie Hôpital Beaujon, AP-HP, and INSERM U 1149, Centre de Recherche sur l’Inflammation Bichat-Beaujon, France</td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>PROTHROMBOTIC GENETIC RISK FACTORS ARE ASSOCIATED WITH LIVER STIFFNESS IN THE GENERAL POPULATION: RESULTS FROM THE ROTTERDAM STUDY</td>
<td>E. Plompen, Erasmus MC University Medical Center, Netherlands</td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>NOVEL 3-DIMENSIONAL MAGNETIC RESONANCE ELASTOGRAPHY ACCURATELY DIAGNOSES NASH AND ADVANCED FIBROSIS IN PATIENTS WITH BIOPSY-PROVEN NAFLD: A PROSPECTIVE COHORT STUDY</td>
<td>R. Loomba, University of California San Diego, United States</td>
</tr>
</tbody>
</table>
17:00-17:15  **COST-EFFECTIVENESS OF NON-INVASIVE LIVER FIBROSIS TESTS FOR TREATMENT DECISIONS IN PATIENTS WITH CHRONIC HEPATITIS C: SYSTEMATIC REVIEW AND ECONOMIC EVALUATION**
E. Tsochatzis, Royal Free Hospital and UCL Institute of Liver and Digestive Health, United Kingdom

17:15-17:30  **CLINICAL UTILITY OF NON-INVASIVE MEASURES OF FIBROSIS IN THE AMBULATORY POPULATION**
T. Nguyen, Virginia Commonwealth University, United States

17:30-17:45  **NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS BY FIBROSCAN IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A META-ANALYSIS WITH INDIVIDUAL DATA**
E. Nguyen-Khac, Amiens University Hospital, France

17:45-18:00  **LIVER STIFFNESS ASSESSED BY FIBROSCAN IS A MAJOR PROGNOSTIC FACTOR IN PRIMARY SCLEROSING CHOLANGITIS**
C. Corpechot, Hôpital Saint-Antoine, APHP, France

### Parallel Session, Capital Suite 11-12

**PUBLIC HEALTH**

16:00-16:15  **SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188)**
S. Deuffic-Burban, IAME, UMR 1137, Inserm, Univ Paris Diderot, Sorbonne Paris Cité, France

16:15-16:30  **EUROPEAN RESPONSES IN FOCUS: COMPARING VIRAL HEPATITIS AND HIV RELATED DEATHS IN EUROPE 1990-2010 IN THE GLOBAL BURDEN OF DISEASE STUDY 2010**
B. Cowie, Victorian Infectious Diseases Reference Laboratory, Australia

16:30-16:45  **FEASIBILITY AND COST ANALYSIS OF COMMUNITY BASED HEPATITIS B SCREENING PROGRAMME IN SUB-SAHARAN AFRICA**
S. Nayagam, Imperial College London, St Mary's Hospital, United Kingdom

16:45-17:00  **CHARACTERISTICS OF UNDIAGNOSED HBV OR HCV CHRONICALLY INFECTED POPULATION IN FRANCE: A NEED FOR RECONSIDERING TESTING STRATEGIES**
C. Brouard, French Institute for Public Health Surveillance (InVS), France

17:00-17:15  **IMPACT OF NEW DAA-CONTAINING REGIMENS ON HCV TRANSMISSION AMONG INJECTING DRUG USERS (IDUS): A MODEL-BASED ANALYSIS (ANRS 12376)**
A. Cousien, IAME, UMR 1137, INSERM, France

17:15-17:30  **ASSESSING THE COST-EFFECTIVENESS OF FINDING CASES OF HEPATITIS B INFECTION IN UK MIGRANT POPULATIONS**
N. Martin, University of Bristol, United Kingdom

17:30-17:45  **EVIDENCE OF REINFECTION WITH HEPATITIS C FOLLOWING SUCCESSFUL TREATMENT WITH ANTIVIRAL THERAPY AMONG PEOPLE WHO INJECT DRUGS IN SCOTLAND**
A. Weir, Glasgow Caledonian University, United Kingdom

17:45-18:00  **HEPATITIS C VIRUS INCIDENCE IN THE AMSTERDAM COHORT STUDY AMONG MEN WHO HAVE SEX WITH MEN; 1984-2011**
J. Vanhommerig, Public Health Service of Amsterdam, Netherlands
### Parallel Session, Capital Suite 2-3-4

**16:00-18:00** **LIVER TUMOURS: EXPERIMENTAL**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td><strong>GENE EXPRESSION-BASED PROGNOSTIC SIGNATURE AND GENOMIC CHARACTERIZATION OF FIBROLAMELLAR HEPATOCELLULAR CARCINOMA</strong></td>
<td>H. Cornella, HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), Liver Unit, Hospital Clinic, IDIBAPS, CIBEREHD, University of Barcelona, Spain</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td><strong>NEDDYLYATION CONTROLS LIVER TUMOURS SURVIVAL STABILIZING AKT AND LKB1 AND REPROGRAMMING CANCER METABOLISM</strong></td>
<td>L. Barbier-Torres, CIC bioGUNE Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain</td>
</tr>
<tr>
<td>16:30-16:45</td>
<td><strong>NF-κB-DEPENDENT AND INDEPENDENT ROLES OF NEMO (IKKγ) IN THE DEVELOPMENT OF CHRONIC LIVER INFLAMMATION AND HCC</strong></td>
<td>V. Kondylis, Institute for Genetics, Germany</td>
</tr>
<tr>
<td>16:45-17:00</td>
<td><strong>HEMATOPOIETIC CELLS-DERIVED JNK1 DRIVES HEPATIC INJURY AND HEPATOCELLULAR CARCINOMA IN IKKγ/NEMO-DELETED LIVERS</strong></td>
<td>F.J. Cubero, University Hospital Aachen, Germany</td>
</tr>
<tr>
<td>17:00-17:15</td>
<td><strong>GUT-DERIVED FGF15 PLAYS A CENTRAL ROLE IN FIBROSIS-ASSOCIATED HEPATOCARCINOCGENESIS</strong></td>
<td>I. Uriarte, CIMA, University of Navarra, Spain</td>
</tr>
<tr>
<td>17:15-17:30</td>
<td><strong>T-CELL RE-DIRECTION AGAINST GLYPICAN-3 FOR IMMUNOTHERAPY OF HEPATOCELLULAR CARCINOMA (HCC)</strong></td>
<td>C. Dargel, Technische Universität München/ Institute of Virology, Germany</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td><strong>INFLAMMATORY WNT DRIVES INTRAHEPATIC CHOLANGIOCARCINOMA GROWTH AND CAN BE THERAPEUTICALLY INHIBITED IN VIVO TO REDUCE TUMOUR BURDEN</strong></td>
<td>L. Boulter, MRC Centre for Regenerative Medicine, United Kingdom</td>
</tr>
<tr>
<td>17:45-18:00</td>
<td><strong>DISCOVERY OF NOVEL MUTATIONS AND FUSION PROTEINS IN INTRAHEPATIC CHOLANGIOCARCINOMA</strong></td>
<td>D. Sia, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain</td>
</tr>
</tbody>
</table>

### Parallel Session, Capital Suite 15-16

**16:00-18:00** **HEPATITIS B & D: EXPERIMENTAL**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td><strong>INTERFERON γ AND TUMOR NECROSIS FACTOR α TREATMENT INDUCE COVALENTLY CLOSED CIRCULAR DNA DEGRADATION IN HEPATITIS B VIRUS INFECTED HEPATOCYTES</strong></td>
<td>Y. Xia, Technische Universität München / Helmholtz Zentrum München, Germany</td>
</tr>
<tr>
<td>16:15-16:30</td>
<td><strong>PROLIFERATION OF HBV-INFECTED HUMAN HEPATOCYTES IN HUMANIZED MICE PROMOTES THE OCCURRENCE OF VIRAL INTEGRATIONS WITHIN THE HOST GENOME</strong></td>
<td>L. Allweiss, University Center Hamburg-Eppendorf, Germany</td>
</tr>
<tr>
<td>16:30-16:45</td>
<td><strong>TRANSCRIPTOME ANALYSIS OF EXHAUSTED VIRUS-SPECIFIC CD8 T CELLS IN CHRONIC HBV INFECTION IDENTIFIES PROFOUND METABOLIC AND FUNCTIONAL CELL DEFECTS</strong></td>
<td>P. Fisicaro, Azienda Ospedaliero-Università di Parma, Italy</td>
</tr>
</tbody>
</table>
16:45-17:00  CYTOLYTIC EFFECTOR FUNCTIONS PREDOMINATE IN CD8+ T-CELL AND NK-CELL MEDIATED INHIBITION OF VIRAL REPLICATION IN HBV INFECTED HEPATOCYTES OVEREXPRESSING SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE
A. Hoh, University Hospital Freiburg, Germany

17:00-17:15  MICE WITH HUMAN LIVERS AS A NEW MODEL OF HEPATITIS E VIRUS INFECTION AND PRECLINICAL DRUG EVALUATION
M. Lutgehetmann, University Medical Center Hamburg-Eppendorf, Germany

17:15-17:30  CLONAL HEPATOCYTE REPOPULATION IN THE YOUNG ADULT HBV INFECTED LIVER CHALLENGES THE CONCEPT OF A GENERIC IMMUNE TOLERANT DISEASE PHASE
P. Kennedy, Blizard Institute, Barts and The London School of Medicine & Dentistry, QMUL, United Kingdom

17:30-17:45  ANTIVIRAL ACTIVITY OF VARIOUS INTERFERONS (IFNS) AND INFLAMMATORY CYTOKINES IN RELEVANT HEPATOCYTE MODELS OF PERSISTENT HEPATITIS B VIRUS (HBV) INFECTION
N. Isorce, Cancer Research Center of Lyon (CRCL) INSERM U 1052, France

17:45-18:00  NATURALLY OCCurring HBV CORE DELETION MUTANTS ENCODE CORE-POLYMERASE FUSION PROTEINS WHICH BIND TO MICRORNAs PERTURBING THE REGULATORY FUNCTION AND ENHANCING HEPATOMA CELL GROWTH
C.-T. Yeh, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan

Highlights from the Literature, Capital Suite 6

16:30-18:00  RECENT HIGHLIGHTS FROM THE LITERATURE: ASK THE AUTHORS
M. Heim, University Hospital Basel, Switzerland

16:30-17:00  SPECIFIC AND NONHEPATOTOXIC DEGRADATION OF NUCLEAR HEPATITIS B VIRUS CCCDNA
U. Protzer, Institute of Virology, TUM, Germany

17:00-17:30  ENDOTHELIAL CELL-DERIVED ANGIOPOIETIN-2 CONTROLS LIVER REGENERATION AS A SPATIOTEMPORAL RHEOSTAT
C. Molger, Germany

17:30-18:00  THE THIRD SIGNAL CYTOKINE IL-12 RESCUES THE ANTI-VIRAL FUNCTION OF EXHAUSTED HBV-SPECIFIC CD8 T CELLS
A. Schurich, University College London, Division of Infection and Immunity, United Kingdom

Industry Satellite Symposia, ICC Capital Hall

18:30-20:00  THE FATE OF VIRAL HEPATITIS ASSOCIATED DISEASES
M. Manns, Medical School of Hannover, Germany
S. Wiktor, World Health Organization (WHO), Switzerland

INTRODUCTION
S. Wiktor, World Health Organization (WHO), Switzerland

THE BURDEN OF VIRAL HEPATITIS IN EUROPE
A. Hatzakis, Greece

WHAT CAN WE ACHIEVE BY INCREASING SVR AND TREATMENT ACCESS IN HEPATITIS C?
H. Wedemeyer, Hannover Medical School, Germany
FUTURE CHALLENGES IN HEPATITIS B AND D
P. Lampertico, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Italy

THE FUTURE OF HEPATOCELLULAR CARCINOMA (HCC)
M. Peck-Radosavljevic, , Austria

OUTLOOK TO THE GLOBAL VIRAL HEPATITIS SUMMIT 2015
M. Manns, Medical School of Hannover, Germany

18:30-20:00 HCC EXPERT PANEL – ADDRESSING HOT TOPICS IN CLINICAL PRACTICE TODAY TO MAXIMIZE OUTCOMES TOMORROW
P. Mathurin, Hôpital Claude Huriez, France

WELCOME AND INTRODUCTION
P. Mathurin, Hôpital Claude Huriez, France

HOW CAN WE OPTIMIZE IMAGING FOR THERAPEUTIC STRATEGIES IN HCC?
P. Mathurin, Hôpital Claude Huriez, France

CURRENT CHALLENGES FACING PHYSICIANS FOR EARLY TREATMENT
M. Wörns, , Germany

IMAGING STRATEGIES TO GUIDE THERAPEUTIC DECISION-MAKING
I. Bargellini, , Italy

HOW CAN WE MAXIMIZE CLINICAL OUTCOMES IN PATIENTS WITH INTERMEDIATE HCC?
P. Mathurin, Hôpital Claude Huriez, France

USING THE RIGHT CRITERIA AT THE RIGHT TIME: TREATMENT OPTIONS AND RESPONSE MEASUREMENT
I. Bargellini, , Italy

EVOLVING TREATMENT STRATEGIES TO EXTEND CLINICAL BENEFIT
W. Sieghart, Medical University of Vienna, Austria

HOW CAN WE OPTIMIZE PATIENT MANAGEMENT WITH SYSTEMIC THERAPIES ACROSS THE SPECTRUM OF HCC?
P. Mathurin, Hôpital Claude Huriez, France

LESSONS LEARNT FROM USING SYSTEMIC THERAPIES
M. Reig, Hospital Clinic, Spain

PUTTING THE THEORY INTO PRACTICE
D. Palmer, , United Kingdom

18:30-20:00 SONOGRAPHY COURSE FOR THE ADVANCED
R. de Knegt, , Netherlands
M. Gebel, Center for Internal Medicine, Hannover Medical School, Germany
TUTORS
R. de Knegt, Netherlands
M. Gebel, Center for Internal Medicine, Hannover Medical School, Germany
C. Terkamp, Germany
A. Potthoff, Germany
P. Taimr, Netherlands
D. Sprengers, Academic Medical Center, University of Amsterdam, Netherlands
Saturday, 12. April 2014

07:30-08:30  **NAFLD – DIAGNOSIS AND CURRENT MANAGEMENT**  
C. Oliveira, University of São Paulo School of Medicine, Brazil  
Q. Anstee, Newcastle University, United Kingdom

07:30-08:30  **CHOLESTATIC LIVER DISEASES AND ADVANCES IN TREATMENT**  
M. Trauner, Medical University Vienna, Austria  
G. Hirschfield, University of Birmingham, United Kingdom

07:30-08:00  **TNFα CLEAVING ENZYME (TACE/ADAM 17) IS AN IMPORTANT DRIVER OF CHOLESTASIS-ASSOCIATED LIVER INJURY AND SICKNESS BEHAVIOR DEVELOPMENT**  
H. Nguyen, University of Calgary, Canada

08:00-08:30  **SCLEROSING CHOLANGITIS IS RESISTANT TO IN VIVO MODULATION OF REGULATORY T CELLS**  
F. von Haxthausen, University Medical Center Hamburg-Eppendorf, Germany

07:30-08:30  **CONTROVERSIES IN ALCOHOLIC LIVER DISEASE**  
S. Stewart, , Israel  
A. Louvet, Hôpital Huriez, France

07:30-08:30  **BASELINE LIVER BIOPSY CAN PREDICT RESPONSE TO STEROIDS IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS**  
S.M. Shasthry, Institute of Liver & Biliary Sciences, India

07:30-08:30  **MANAGEMENT OF INFECTIONS IN LIVER DISEASE**  
R. Moreau, Inserm U 773, Hôpital Beaujon, France  
R. Wiest, , Switzerland

07:30-07:40  **PROGNOSIS OF BACTERIAL INFECTION DEPENDS ON ESBL-PRODUCING BACTERIA**

07:40-07:50  **PROGNOSIS OF BACTERIAL INFECTION DEPENDS ON ORGAN FAILURE(S)**

07:50-08:10  **ALBUMIN IS MORE THAN A PLASMA EXPANDER**

08:10-08:30  **ASSESSING PROGNOSIS OF BACTERIAL INFECTION USING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL)**

07:30-08:30  **GUT MICROBIOME IN LIVER DISEASE**  
H. Tilg, , Austria  
P. Cani, , Belgium
07:30-08:00  DOES THE GUT MICROBIOTA MODULATE THE INFLAMMATORY STATE IN CIRRHOTIC HOST?
V. Giannelli, Sapienza University of Rome, Italy

08:00-08:30  STEATOSIS-INDEPENDENT PREVENTION OF LIVER FIBROSIS VIA THE TRANSREPRESSIVE ACTIVITY OF PPARα
M. Pawlak, European Genomic Institute for Diabetes, France

07:30-08:30  EPITHELIAL-MESENCHYMAL INTERACTIONS IN LIVER DISEASE
G. Giannelli, Internal Medicine Unit C. 'Frugoni' University of Bari A. Moro, Italy
I. Fabregat, , Spain

07:30-08:00  DETECTION OF CIRCULATING TUMOUR CELLS (CTCS) IN HEPATOCELLULAR (HCC) CANCER PATIENTS USING THE IMAGESTREAM²
L. Ogle, Newcastle University, United Kingdom

08:00-08:30  MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION
O. García-Irigoyen, Cima. University of Navarra, Spain

07:30-08:30  PROPHYLAXIS OF HEPATITIS B
M. Viganò, Ospedale San Giuseppe,Università degli Studi di Milano, Italy
R. Flisiak, Uniwersytet Medyczny, Poland

07:30-08:30  DIAGNOSIS AND MANAGEMENT OF HEV INFECTION
H. Wedemeyer, Hannover Medical School, Germany
H. Dalton, , United Kingdom

07:30-08:00  DICHTOMAL EFFECT OF IMMUNOSUPPRESSANTS ON HEPATITIS E VIRUS INFECTION: CALCINEURIN INHIBITORS STIMULATE BUT MYCOPHENOLIC ACID INHIBITS VIRAL REPLICATION
Y. Wang, Erasmus MC-University Medical Center, Netherlands

08:00-08:30  POST-INFECTIOUS PERIPHERAL NERVOUS SYSTEM DISORDERS AND HEPATITIS E VIRUS
R. Madden, Royal Cornwall Hospital Trust, United Kingdom

07:30-08:30  DRUG RESISTANCE IN VIRAL HEPATITIS
M. Levrero, University of Rome, Italy
T. Asselah, Hôpital Beaujon, France
Early Morning Workshop, Capital Suite 13

07:30-08:30 HCV MANAGEMENT IN PEOPLE WHO INJECT DRUGS
O. Dalgard, Aker University Hospital, Norway
S. Mauss, Center for HIV and Hepatogastroenterology, Germany

Early Morning Workshop, Capital Suite 5

07:30-08:30 DIRECT ANTI-VIRALS FOR POST-TRANSPLANT HEPATITIS C: INTERFERON-FREE REGIMENS IN REACH?
X. Forns, Hospital Clinic, CIBEREHD and IDIBAPS, Spain
F. Durand, Université Paris VII, Hôpital Beaujon, France

07:30-08:30 IN VIVO ASSESSMENT OF ABC TRANSPORTER ACTIVITY USING [18F]CIPROFLOXACIN AND PET-MR SCANNING IN MICE FED WITH NORURSODEOXYCHOLIC ACID
E. Halilbasic, , Austria

Early Morning Workshop, London Suite 1

07:30-08:30 DIAGNOSIS AND MANAGEMENT OF LONG-TERM SURGICAL AND MEDICAL COMPLICATIONS FOLLOWING LIVER TRANSPLANTATION
P. Burra, Padova University Hospital, Italy

07:30-08:00 CROSS-PRESENTATION OF VIRAL ANTIGEN BY LSEC CAN LEAD TO FULMINANT HEPATITIS
M. Welz, University of Bonn, Germany

08:00-08:30 IMPACT IN DAILY PRACTICE OF THE CONCEPT OF TREATMENT RESPONSE IN PRIMARY BILIARY CIRRHOSIS. A NATIONAL COHORT STUDY

Early Morning Workshop, London Suite 2

07:30-08:30 COMBINATION THERAPIES FOR HCC: HOW TO INDIVIDUALISE THE EASL ALGORITHM?
J. Ricke, Otto-von-Guericke University Magdeburg, Germany
A. Forner, , Spain

General Session, ICC Auditorium

08:30-10:30 GENERAL SESSION 3 & AWARDS 2
M. Bernardi, Alma Mater Studiorum - Università di Bologna, Semeiotica Medica - Policlinico S. Orsola-Malpighi, Italy
A. Kadir Dokmeci, , Turkey

08:30-08:45 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY
N. Afdhal, Beth Israel Deaconess Medical Center, United States

08:45-09:00 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC - IMPLICATIONS FOR SCREENING
P. Johnson, University of Liverpool, United Kingdom
09:00-09:15  SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR+GS-5816 FOR 12 WEEKS IN TREATMENT NAÏVE PATIENTS WITH GENOTYPE 1-6 HCV INFECTION
G. Everson, University of Colorado Denver, United States

09:15-09:45  AWARD CEREMONY II

09:45-10:00  GENERATION OF MICE WITH SYNGENEIC HUMAN LIVER AND IMMUNE SYSTEM TO STUDY CELLULAR IMMUNITY TO HEPATITIS B VIRUS
Y. de Jong, Weill Cornell Medical College, United States

10:00-10:15  COMBINATION THERAPY WITH PEGINTERFERON ALFA-2A AND A NUCLEOS(T)IDE ANALOGUE FOR HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
W.-W. Su, Changhua Christian Hospital, Taiwan

P. Kwo, Indiana University, United States

10:30-11:00  METABONOMIC APPLICATIONS IN LIVER DISEASES
KEYNOTE SPEAKER
E. Holmes, United Kingdom

11:15-13:15  2014 ELPA SYMPOSIUM: ERADICATING HEPATITIS C FROM EUROPE - DREAM OR REALITY?

11:15-11:25  OPENING
G. Foster, Queen Mary University of London, United Kingdom

11:25-11:35  SCREENING FOR HEPATITIS C
A. Amato, United States

11:35-11:45  SUSTAINED ViroLOGICAL RESPONSE TO ANTI-HCV TREATMENTS: A GAMEBREAKER FOR ALL PATIENTS
M. Colombo, Fondazione IRCCS Maggiore Hospital, University of Milan, Italy

11:45-11:55  WHAT THE EUROPEAN COMMISSION CAN DO TO IMPROVE HCV POLICIES AT THE EUROPEAN LEVEL
M. Schuppe, United States

11:55-12:05  WHAT IS THE SENSE OF HCV SCREENING PROGRAMS IF THE PATIENTS WILL HAVE LIMITED ACCESS TO (THE NEW) DRUGS IN EASTERN EUROPEAN COUNTRIES?
A. Vince, Croatia

12:05-12:15  HCV PREVENTION IN THE DAA ERA: MODELLING IMPACT, COST-EFFECTIVENESS, AND AFFORDABILITY IN EUROPE
N. Martin, University of Bristol, United Kingdom

12:15-12:25  HOW TREATMENT ACCESS AND EFFICACY IMPACT HCV ERADICATION IN WESTERN EUROPE
T. Berg, Universitaetsklinik, Germany
12:25-12:35  HEPATITIS C IN 2020: CASE CLOSED, AND PROBLEM SOLVED?
I. van Thiel, ,
I. Gardini, ,
12:35-12:45  PANEL DISCUSSION

Business Meeting, Capital Suite 2-3-4

11:30-12:30  BUSINESS MEETING

eposter, Poster Exhibition - ePoster Oral Session Room A

12:30-13:30  CLINICAL LIVER CANCER

12:30-12:36  ANALYSIS OF THE ADHERENCE TO A HEPATOCELLULAR CARCINOMA (HCC) SURVEILLANCE PROGRAMME BASED ON BIANNUAL CONTROLS

12:36-12:42  NON-SELECTIVE BETA-BLOCKERS MAY REDUCE INCIDENCE OF HEPATOCELLULAR CARCINOMA: A META-ANALYSIS OF RANDOMISED TRIALS

12:42-12:48  MANAGEMENT OF HYPOVASCULAR HYPOINTENSE NODULES ON HEPATOBILIARY PHASE OF GD-EOB-DTPA ENHANCED MRI

12:48-12:54  PROPOSAL FOR AN UPDATE OF THE BARCELONA STAGING SYSTEM FOR HEPATOCELLULAR CARCINOMA BASED ON THE ROLE OF PERFORMANCE STATUS

12:54-13:00  RETREATMENT WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE): THE ABCR SCORE, AN AID TO THE DECISION-MAKING PROCESS

13:00-13:06  CLINICAL OUTCOMES AND SAFETY PROFILE OF TRANSARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA WITH SMALL (70-150 µM, M1) DRUG ELUTING BEADS: A PHASE I STUDY

13:06-13:12  PERSONALIZED THERAPY WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA

eposter, Poster Exhibition - ePoster Oral Session Room B

12:30-13:30  LIVER FIBROSIS

M. Mari, Liver Unit-Hospital Clínic, IIBB-CSIC/IDIBAPS, CIBEREHD, Spain

12:30-12:36  A 5.9 KDA SERUM FRAGMENT OF FIBRINOGEN α-CHAIN IS A SPECIFIC SURROGATE MARKER OF ACTIVE FIBROGENESIS IN PATIENTS WITH LIVER DISEASE

12:36-12:42  A SIMPLE FLUORESCENCE BASED METHOD TO NON-INVASIVELY IMAGE LIVER FIBROSIS

12:42-12:48  HEPATIC STELLATE CELLS ARE THE MAIN SOURCE OF MYOFIBROBLASTS IN A MOUSE MODEL OF CHRONIC CHOLESTATIC LIVER DISEASE

12:48-12:54  INTEGRIN B1 REGULATES HEPATIC STELLATE CELL ACTIVATION VIA THE ACTIN MYOSIN CYTOSKELETON

12:54-13:00  NCU-G1GT/GT MICE: A LONG-LIVED MODEL FOR LIVER FIBROSIS

13:00-13:06  PROMOTION OF LIVER INJURY AND FIBROSIS BY THE LIVER-DERIVED PLASMA PROTEIN HISTIDINE-RICH GLYCOPROTEIN IS BASED ON POLARIZING HEPATIC MACROPHAGES TOWARDS THE INFLAMMATORY M1 PHENOTYPE

13:06-13:12  REGULATION OF LIVER FIBROSIS BY TUNING M2 MACROPHAGE POLARIZATION THROUGH IL-4RALPHA INHIBITION
Scientific Programme

eposter, Poster Exhibition - ePoster Oral Session Room C

12:30-13:30 **CHOLESTASIS**

P. Fickert, , Austria

12:30-12:36 **THE NATURAL HISTORY OF AUTOIMMUNE HEPATITIS (AIH) PRESENTING WITH JAUNDICE**

12:36-12:42 **PREDICTION OF SHORT- AND LONG-TERM OUTCOME IN PATIENTS WITH AUTOIMMUNE HEPATITIS**

12:42-12:48 **CHARACTERIZATION AND OUTCOME OF ANTIMITOCHONDRIAL TYPE 2-POSITIVE PATIENTS WITHOUT A DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS: A FRENCH NATIONWIDE PROSPECTIVE STUDY**

12:48-12:54 **COGNITIVE AND EMOTIONAL PROCESSING NETWORKS ARE IMPACTED BY SENSORY INPUT TO THE THALAMUS IN PATIENTS WITH PRIMARY BILIARY CHIRRHOSIS**

12:54-13:00 **CHOLESTATIC ABCB4-DEFICIENT MICE REVEAL DEPRESSION/ANXIETY-LIKE BEHAVIOR**

13:00-13:06 **ACTIVATION OF THE DEVELOPMENTAL PATHWAY NGN-3/MIR-7A REGULATES CHOLANGIOCYTES PROLIFERATION IN RESPONSE TO INJURY**

13:06-13:12 **SCLEROSING CHOLANGITIS IS RESISTANT TO IN VIVO MODULATION OF REGULATORY T CELLS**

eposter, Poster Exhibition - ePoster Oral Session Room D

12:30-13:30 **TRANSPLANTATION AND ACUTE LIVER FAILURE**

12:30-12:36 **THE LOSS OF PROLIFERATIVE COMPETITIVENESS OF AGED HEPATOCYTES**

12:36-12:42 **REVERSIBLE NON-ISCHEMIC CARDIOMYOPATHY WITH SEVERE LEFT VENTRICULAR DYSFUNCTION AFTER LIVER TRANSPLANTATION**

12:42-12:48 **OBESITY IS NOT ASSOCIATED WITH WORSE POST-LIVER TRANSPLANTATION SURVIVAL**

12:48-12:54 **CIRCULATING MIRNA-122/LET-7D RATIO, HEPATITIS C VIRUS LOAD AND FIBROSING CHOLESTATIC HCV RECURRENT AFTER LIVER TRANSPLANTATION**

12:54-13:00 **DONOR/RECIPIENT GENDER MISMATCH MODIFIES THE IMPACT OF DONOR AGE ON GRAFT SURVIVAL FOLLOWING LIVER TRANSPLANTATION**

13:00-13:06 **FULMINANT PRESENTATION OF AUTOIMMUNE HEPATITIS: PATHOLOGICAL FEATURES AND STEROID RESPONSE**

13:06-13:12 **DELETERIOUS OUTCOME IN PATIENTS WITH ACUTE LIVER INJURY**

Symposia, ICC Capital Hall

13:30-15:00 **EASL CLINICAL SYMPOSIUM: CONTROVERSIES IN LIVER TRANSPLANTATION**

D.J. Mutimer, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, United Kingdom

13:30-14:00 **CAN IMMUNOSUPPRESSION BE WITHDRAWN COMPLETELY IN SELECTED LIVER TRANSPLANT PATIENTS?**

T. Wekerle, , Austria

14:00-14:30 **WHICH HCV-INFECTED HIV-POSITIVE RECIPIENTS ARE SUITABLE LIVER TRANSPLANT CANDIDATES?**

J.-C. Duclos-Vallées, , France
14:30-15:00  TRANSPLANTATION OR CONSERVATIVE MANAGEMENT FOR PATIENTS WITH HEPATOPULMONARY SYNDROME AND PORTOPULMONARY HYPERTENSION - HOW TO DECIDE?
J. Ferguson, United Kingdom

Symposia, Capital Suite 7-8-9

13:30-15:00  EASL CLINICAL SYMPOSIUM: TREATMENT OF OBESITY
S. Zelber-Sagi, Dept. Gastroenterology, Tel Aviv Sourasky Medical Center, Israel

13:30-13:40  INTRODUCTION TO THE OBESITY EPIDEMIC AND CURRENT TREATMENT APPROACHES
S. Zelber-Sagi, Dept. Gastroenterology, Tel Aviv Sourasky Medical Center, Israel

13:40-14:05  DEFEATING DIABESITY: THE CASE FOR PERSONALIZED COMBINATORIAL DRUG THERAPIES
M. Tschoep, Germany

14:05-14:30  ENDOCRINE MECHANISMS IN WEIGHT REDUCTION FOLLOWING BARIATRIC SURGERY
J. Pinkney, United Kingdom

14:30-14:55  NOVEL INSIGHTS ON THE ROLES OF BROWN AND BRITE VERSUS WHITE ADIPOCYTES IN OBESITY AND THE METABOLIC SYNDROME
J. Heeren, Germany

14:55-15:00  DISCUSSION

Symposia, Capital Suite 11-12

13:30-15:00  EASL BASIC SYMPOSIUM: VIRAL RECEPTORS AND INHIBITORS OF VIRAL ENTRY
S. Urban, Germany

13:30-13:50  MECHANISMS AND INHIBITION OF VIRUS ENTRY
A. Helenius, Switzerland

13:50-14:10  RECOMBINANT HUMAN NEUTRALIZING ANTIBODIES AS FUTURE ANTIVIRAL AGENTS
A. Lanzavecchia, Switzerland

14:10-14:30  HCV RECEPTORS, ENTRY-MEDIATING SIGNALING CASCADES AND POSSIBLE TARGETS TO INHIBIT ENTRY
T. Baumert, France

14:30-14:50  MYRCLUDEX B, AN NTCP-SPECIFIC INHIBITOR OF HBV AND HDV ENTRY: PRECLINICAL DATA AND FIRST EFFICACY RESULTS OF A PHASE IIA STUDY
S. Urban, Germany

14:50-15:00  DISCUSSION

Young Investigator, Capital Suite 2-3-4

13:30-15:00  YI FORUM 2014: HOW TO FUND YOUR RESEARCH?
H. Wedemeyer, Hannover Medical School, Germany
G. Germani, Italy
13:30-13:40  INTRODUCTION: PRESENTATION OF YI-CAG, HOW TO GET INVOLVED, BENEFITS FROM YI-CAG  
P.-E. Rautou, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, France

13:40-14:00  EXISTING EUROPEAN (EASL AND EU) FUNDING OPPORTUNITIES  
D.-C. Valla, , France

14:00-14:20  HOW TO WRITE HIS/HER CV?  
H. Wedemeyer, Hannover Medical School, Germany

14:20-14:40  HOW TO WRITE A GRANT/FELLOWSHIP APPLICATION: THE GRANT REVIEWER POINT-OF-VIEW  
M. Pinzani, , United Kingdom

14:40-15:00  HOW THE INDUSTRY CAN CONTRIBUTE TO YI RESEARCH: THE INDUSTRY POINT OF VIEW  
J. McHutchison, , United States

13:30-15:00  EASL CLINICAL SYMPOSIUM: HEPATITIS B AND C: CONTROLLING AND PREVENTING TRANSMISSION  
D. Goldberg, , United Kingdom

13:30-14:00  EPIDEMIOLOGY AND IMPORTANCE OF MONITORING  
S. Hutchinson, , United Kingdom

14:00-14:30  FUTURE VACCINATION CHALLENGES AND THE POTENTIAL ROLE OF THE NEW ANTIVIRAL THERAPIES  
D. Shouval, , Israel

14:30-15:00  NON-VACCINE/Therapeutic INTERVENTIONS TO INTERRUPT TRANSMISSION  
S. Wiktor, World Health Organization (WHO), Switzerland

14:00-15:00  NEW EASL ONLINE RECOMMENDATIONS ON THE MANAGEMENT OF HEPATITIS C  
J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France  
M. Peck-Radosavljevic, , Austria

DISCUSSION PANEL  
A. Aghemo, , Italy  
G. Dusheiko, , United Kingdom  
X. Forns, Hospital Clinic, CIBEREHD and IDIBAPS, Spain  
M. Puoti, AO Ospedale Niguarda Cà Granda, Italy  
C. Sarrazin, J. W. Goethe-University Hospital, Germany

15:30-17:30  LATE BREAKERS  
P. Ferenci, Medical University of Vienna, Austria  
J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France
15:30-15:45 TURQUOISE-II: SVR12 RATES OF 92%-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/RI/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)
F. Poordad, The Texas Liver Institute/University of Texas Health Science Center, United States

15:45-16:00 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY
A. Mangia, IRCCS ‘Casa Sollievo della Sofferenza’ Hospital, Italy

16:00-16:15 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3-4 (COHORT 2)
E. Lawitz, The Texas Liver Institute, University of Texas Health Science Center, United States

16:15-16:30 ALL-ORAL DUAL THERAPY WITH DACA/TASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS
M. Manns, Medical School of Hannover, Germany

16:30-16:45 ADDITION OF SIMVASTATIN TO STANDARD TREATMENT IMPROVES SURVIVAL AFTER VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS. A DOUBLE-BLIND RANDOMIZED TRIAL (NCT01095185)
J.G. Abraldes, Hospital Clinic. Ciberehd, Spain

16:45-17:00 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES - AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS
F. Nevens, UZ Leuven, Belgium

17:00-17:15 RIFAXIMIN VERSUS LACTULOSE IN THE TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS: A PROSPECTIVE, RANDOMIZED, ACTIVE-COMPARATOR, NON-INFERIORITY TRIAL
O. Goyal, D.M.C. and Hospital, India

17:15-17:30 DYSREGULATED UNFOLDED PROTEIN RESPONSE CONTROL IN THE ABSENCE OF CANONICAL IKK/NF-κB SIGNALLING LEADS TO SEVERE LIVER DAMAGE AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA
Y. Sunami, Klinikum rechts der Isar, Technical University Munich, Germany

Parallel Session, Capital Suite 7-8-9

15:30-17:30 HEPATITIS B & E: CLINICAL
M. Brunetto, University Hospital of Pisa, Italy
J.D. Jia, China

15:30-15:45 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBEAG-POSITIVE DISEASE
H. Chan, Chinese University of Hong Kong, China

15:45-16:00 HEPATITIS B SURFACE ANTIGEN (HBSAG) LEVELS DIFFER ACROSS HBV GENOTYPE AND PHENOTYPE: RESULTS FROM THE ADULT COHORT STUDY OF THE NIDDK-SPONSORED HEPATITIS B RESEARCH NETWORK
W.P. Brouwer, Willem Pieter Brouwer, Netherlands

16:00-16:15 SEQUENTIAL COMBINATION THERAPY WITH NUCS AND PEG-INF IN HBEAG POSITIVE CHB PATIENTS WITH PRIOR EXPOSURE TO LONG-TERM OF NUCS
W. Zhang, Huashan Hospital, Fudan University, China
### 16:15-16:30

**A MUTATION IN THE HEPATITIS E VIRUS POLYMERASE ASSOCIATED WITH RIBAVIRIN TREATMENT FAILURE HAS A REPLICATION ADVANTAGE IN VITRO**  
Y. Debing, University of Leuven, Rega Institute for Medical Research, Belgium

### 16:30-16:45

**IN VIVO INHIBITION OF HBV ANTIGENEMIA AND VIREMIA BY ANTISENSE OLIGONUCLEOTIDES**  
G. Billioud, The Scripps Research Institute, United States

### 16:45-17:00

**REDUCED INCIDENCE OF HEPATOCELLULAR CARCINOMA IN HIV/HBV-COINFECTED PATIENTS RECEIVING TENOFOVIR**  
G. Wandeler, Department of Infectious Diseases, Bern University Hospital, Switzerland

### 17:00-17:15

**SCI-B-VAC IS SUPERIOR TO ENGERIX-B FOR PREVENTING HBV VERTICAL TRANSMISSION**  
R. Safadi, Hadassah-Hebrew University Hospital, Israel

### 17:15-17:30

**EFFECTIVENESS OF TENOFOVIR DF FOR CHRONIC HEPATITIS B IN FIELD PRACTICE - 3 YEAR FINAL RESULTS FROM THE PROSPECTIVE GERMAN MULTICENTER NON-INTERVENTIONAL STUDY**  
J. Petersen, IFI Institute at the, Asklepios Klinik St Georg Hamburg, Germany

---

### Parallel Session, Capital Suite 11-12

#### 15:30-17:30

**LIVER TUMOURS MANAGEMENT**  
K.H. Han, H. Reeves, Newcastle University Medical School, United Kingdom

### 15:30-15:45

**POST SORAFENIB SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: THE ROLE OF TUMOR PROGRESSION AND LIVER IMPAIRMENT**  
M. Iavarone, Fondazione IRCCS Ca’ Granda Maggiore Hospital Milan, Italy

### 15:45-16:00

**A BLOOD-BASED 3-GENE SIGNATURE WITH SUFFICIENT SENSITIVITY AND SPECIFICITY TO DETECT EARLY STAGE HUMAN HEPATOCELLULAR CARCINOMA IN HIGH-RISK PATIENTS WITH CHRONIC HEPATITIS AND CIRRHOSIS**  
K. Hui, National Cancer Centre Singapore, Singapore

### 16:00-16:15

**HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN CHRONIC HEPATITIS C PATIENTS (CHC) ACCORDING TO SUSTAINED VIROLOGIC RESPONSE (SVR) AND BASELINE CHARACTERISTICS**  
T. Purevsambuu, Medical University of Vienna, Austria

### 16:15-16:30

**EVALUATION OF LY2157299 MONOHYDRATE(LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD**  
G. Giannelli, Internal Medicine Unit C. 'Frugoni' University of Bari A. Moro, Italy

### 16:30-16:45

**STAGING EARLY HEPATOCELLULAR CARCINOMA WITH GADOXETIC ACID-ENHANCED MAGNETIC RESONANCE IMAGING AND IMPROVEMENT IN SURVIVAL**  
H.-D. Kim, Asan Medical Center, University of Ulsan College of Medicine, Korea, Republic of

### 16:45-17:00

**SURGICAL RESECTION VERSUS RADIOFREQUENCY ABLATION IN THE TREATMENT OF PATIENTS WITH SOLITARY HEPATOCELLULAR CARCINOMA WITHOUT PORTAL HYPERTENSION: A 10-YEAR OUTCOME STUDY**  
G.-A. Kim, Asan Medical Center, University of Ulsan College of Medicine, Korea, Republic of

### 17:00-17:15

**VALIDATION OF THE BCLC-B SUBCLASSIFICATION IN AN AUSTRIAN TACE COHORT**  
F. Hucke, Medical University of Vienna, Austria
17:15-17:30  DONOR CHARACTERISTICS AND THE RISK OF HEPATOCELLULAR CARCINOMA RECURRENT AFTER LIVER TRANSPLANTATION
L. A. Orci, Geneva University Hospitals, Switzerland

Parallel Session, Capital Suite 2-3-4

15:30-17:30  CHOLESTATIC AND GENETIC LIVER DISEASES. PEDIATRICS
T. H. Karlsen, Oslo University Hospital, Rikshospitalet, Norway
F. Lammert, Saarland University Hospital, Germany

15:30-15:45  GENOME-WIDE ASSOCIATION STUDY IN AUTOIMMUNE HEPATITIS IDENTIFIES RISK VARIANT IN THE SH2B3 REGION
Y. de Boer, VU University Medical Center, Netherlands

15:45-16:00  EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY
P. Trivedi, University of Birmingham, United Kingdom

16:00-16:15  NOVEL PROTEIN MARKERS IDENTIFIED IN BILE AND SERUM ARE ASSOCIATED WITH A DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS, DISEASE SEVERITY, AND TRANSPLANT-FREE SURVIVAL
M. Vesterhus, Oslo University Hospital Rikshospitalet, Norway

16:15-16:30  IDENTIFYING APPROACHES TO INTERVENTION IN PRIMARY SCEROSING CHOLANGITIS (PSC): EFFECTOR FUNCTIONS OF CD28 NEGATIVE T CELLS AND THEIR MODULATION BY VITAMIN D
E. Liaskou, University of Birmingham, United Kingdom

16:30-16:45  INHIBITION OF INTESTINAL BILE ACID ABSORPTION BY ASBT INHIBITOR A4250 PROTECTS AGAINST BILE ACID-MEDIATED CHOLESTATIC LIVER INJURY IN MICE
A. Baghdasaryan, Medical University of Vienna, Austria

16:45-17:00  A NOVEL, HYBRID RECOMBINANT AAV-PIGGYBAC TRANSPONSON VECTOR PERMITS ROBUST LONG-TERM PHENOTYPE CORRECTION OF THE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 3 MOUSE MODEL IN VIVO
S. Siew, Children's Medical Research Institute, Australia

17:00-17:15  4-PHENYLBUTYLATE AMELIORATES LIVER FIBROSIS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) TYPE 2 AND PRURITUS IN PATIENTS WITH PFIC TYPE 1
Y. Hasegawa, Graduate School of Medicine, Osaka University, Japan

17:15-17:30  PHASE 1 CLINICAL TRIAL OF LIVER DIRECTED GENE THERAPY WITH RAAV5-PBGD IN ACUTE INTERMITTENT PORPHYRIA: PRELIMINARY SAFETY DATA
D. D'Avola, Clinica Universidad de Navarra, Spain

Parallel Session, Capital Suite 14

15:30-17:30  ALCOHOL AND DRUG INDUCED LIVER DISEASES
R. J. Andrade, Unidad de Gestión Clínica de Enfermedades Digestivas, Servicio de Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, CIBERehd, Spain
C. P. Day, Newcastle University, Newcastle University Medical School, United Kingdom
15:30-15:45  ALCOHOLIC HEPATITIS RESISTANT TO MEDICAL THERAPY IS CHARACTERIZED BY AN ALTERED DIFFERENTIATION OF HEPATIC PROGENITORS UNDER THE INFLUENCE OF EXTRACELLULAR MATRIX
L. Dubuquoy, Inserm-Université Lille 2, France

15:45-16:00  INTEGRATIVE MICRORNA PROFILING IDENTIFIES MIR-21 AND MIR-155 AS POTENTIAL REGULATORS IN ALCOHOLIC HEPATITIS
D. Blaya, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain

16:00-16:15  SIRS AT ADMISSION IS A PREDICTOR OF AKI DEVELOPMENT AND MORTALITY IN HOSPITALIZED PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS
R. Maiwall, ILBS, India

16:15-16:30  CLOSTRIDIUM DIFFICILE INFECTION AND ALCOHOLIC HEPATITIS: THE ASSOCIATED RISK, MORTALITY, AND HEALTH CARE UTILIZATION
V. Sundaram, Cedars-Sinai Medical Center, United States

16:30-16:45  SPARC (SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE) DEFICIENCY PROTECTS FROM CONCANAVALIN A-INDUCED HEPATITIS IN MICE
E. Peixoto, Gene Therapy Laboratory, Facultad de Ciencias Biomédicas, Universidad Austral, Argentina

16:45-17:00  M65 AND M30 AS HIGHLY SENSITIVE MARKERS OF ALCOHOLIC STEATOHEPATITIS
S. Mueller, Department of Internal Medicine, Salem Medical Center and Center for Alcohol Research, University of Heidelberg, Germany

17:00-17:15  THE REGULATORY INTERPLAY BETWEEN JNK1 AND JNK2 IS A SIN EQUONAN CONDITION AGAINST DRUG-INDUCED LIVER TOXICITY
F.J. Cubero, University Hospital Aachen, Germany

17:15-17:30  INTESTINAL DYSBIOSIS EXPLAINS INTER-INDIVIDUAL DIFFERENCES IN SUSCEPTIBILITY TO ALCOHOLIC LIVER DISEASE
M. Llopis, INSERM, France

Parallel Session, Capital Suite 17

15:30-17:30  MOLECULAR AND CELLULAR BIOLOGY: HSC FIBROSIS. CIRRHOSIS, PATHOPHYSIOLOGY
C. Rodrigues, , Portugal
M. Fernandez, , Spain

15:30-15:45  HEPATIC STELLATE CELLS ARE THE MAJOR SOURCE OF COLLAGEN IN MURINE MODELS OF LIVER FIBROSIS
C. Österreicher, Medical University of Vienna, Institute of Pharmacology, Austria

15:45-16:00  KLF2 UP-REGULATION DECREASES HEPATIC FIBROSIS AND AMELIORATES ENDOTHELIAL DYSFUNCTION IN CIRRHOTIC RATS
G. Marrone, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, CIBERehd, University of Barcelona Medical School, Spain

16:00-16:15  TARGETING REV-ERBα-REGULATED TENASCIN-C EXPRESSION IN HEPATIC STELLATE CELLS TO MODULATE CTGF/TGFβ1 SIGNALING IN HEPATIC FIBROSIS
L. Schrum, Carolinas Medical Center, United States
16:15-16:30  LOSS OF GATA4 IN HEPATIC STELLATE CELLS PROMOTES LIVER FIBROSIS  
A. Rojas, Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER)-Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain

16:30-16:45  LOSS OF β1-INTEGRIN IN HEPATOCYTES INDUCES LIVER FIBROSIS  
E. Altrock, Max-Planck Institute for Biochemistry, Germany

16:45-17:00  THE SPlicing FACTOR SLU7 IS ESSENTIAL FOR THE PRESERVATION OF LIVER DIFFERENTIATION, METABOLIC FUNCTION AND QUIESENCE  
M. Elizalde, CIMA-University of Navarra, Spain

17:00-17:15  THE FARNESOID X RECEPTOR AGONIST, OBRETICOLIC ACID, IMPROVES INTESTINAL ANTIBACTERIAL DEFENSE AND REDUCES GUT BACTERIAL TRANSLLOCATION AND HEPATIC FIBROGENESIS IN CCL4-CIRRHOTIC RATS WITH ASCITES  
A. Albillos, University of Alcala, Spain

17:15-17:30  PROSTAGLANDIN E2 MEDIATES IMMUNOSUPPRESSION IN ACUTELY DECOMPENSATED CIRRHOSIS  
A. O'Brien, University College London (UCL), United Kingdom

Parallel Session, Capital Suite 1

15:30-17:30  LIVER IMMUNOLOGY  
F. Tacke, G. Vergani

15:30-15:45  HOMOZYGOUS NLG4-/- (KO) MICE SHOWED A DECREASED INFLAMMATORY AND FIBROTIC PROFILE AND IS ASSOCIATED WITH NK CELLS INCREASED KILLING ACTIVITY  
J. Amer, Hadassah-Hebrew University Hospital, Israel

15:45-16:00  MITOCHONDRIA PLAY A CENTRAL ROLE IN A NOVEL INNATE IMMUNE SENSING MECHANISM OF VIRAL INFECTION IN HEPATOCYTES  
M. Janas, University of Bonn, Germany

16:00-16:15  VIRUS INFECTION OF HEPATIC SINUSOIDAL ENDOTHELIAL CELLS REGULATES HEPATIC T CELL RECRUITMENT AND ACTIVATION  
T. Bruns, Department of Internal Medicine II, Jena University Hospital, Germany

16:15-16:30  A PROTECTIVE HLA-B*27 EPITOPE CONTRIBUTES TO HCV CONTROL IN CHRONIC INFECTION DESPITE PRESENCE OF VIRAL ESCAPE MUTATIONS AND IS CHARACTERIZED BY A UNIQUE T-CELL PHENOTYPE  
B. Martin, Medical Center, University of Freiburg, Germany

16:30-16:45  PDGF SENSITIZE CANCER-ASSOCIATED FIBROBLASTS TO APOPTOSIS IN A PUMA-DEPENDENT MANNER  
S. Rizvi, Mayo Clinc, United States

16:45-17:00  RAPAMYCIN AND EVEROLIMUS FACILITATE HEPATITIS E VIRUS REPLICATION REVEALING A HEPATOCYTE-SPECIFIC PI3K-AKT-MTOR-DEPENDENT DEFENSE MECHANISM  
X. Zhou, Erasmus MC University Medical Center, Netherlands

17:00-17:15  CROSS-REACTIVITY OF HCV SPECIFIC, VACCINE INDUCED T CELLS, USING AN IN VITRO PRIMING MODEL  
C. Kelly, University of Oxford, United Kingdom
17:15-17:30  THE FREQUENCY OF ANTIGEN EXPRESSING HEPATOCYTES DETERMINES THE EFFICACY OF THERAPEUTIC VACCINATION  
M. Cebula, Helmholtz Centre for Infection Research, Germany

Major Satellite Symposia, ICC Auditorium

18:00-19:30  ACHIEVING SUCCESS FOR HCV PATIENTS THROUGH REAL-WORLD EXPERIENCE

18:00-18:15  20 YEARS OF HCV THERAPY AND BEYOND  
T. Berg, Universitaetsklinik, Germany

18:15-18:35  TREATMENT DECISIONS IN 2011 AND 2014: LESSONS LEARNED FROM THE REAL-WORLD  
R. Esteban, Vall d'Hebron Hospital, Spain

18:35-18:55  THE IMPORTANCE OF INDIVIDUALISED CARE IN PATIENT SUBPOPULATIONS  
M. Puoti, AO Ospedale Niguarda Cà Granda, Italy

18:55-19:20  ACHIEVING FUTURE SUCCESS: IS ERADICATION POSSIBLE?  
G. Dusheiko, , United Kingdom

19:20-19:30  Q&A

Major Satellite Symposia, ICC Capital Hall

18:00-19:30  ALL PATIENTS, ALL GENOTYPES, ALL ORAL – ARE WE THERE YET?  
M. Thursz, , United Kingdom

NEWS AT 6: OPENING HEADLINES  
M. Thursz, , United Kingdom

STOP THE PRESS! A CRITICAL EVALUATION OF HCV TREATMENT TARGETS FOR PATIENTS OF ALL GENOTYPES  
J.-M. Pawlotsky, Hôpital Henri Mondor, Department of Virology, France

THE BIG DEBATE: HAS THE TIME COME FOR ALL-ORAL INTERFERON/ RIBAVIRIN-FREE REGIMENS?  
H. Wedemeyer, Hannover Medical School, Germany  
A. Brown, , United Kingdom

THE EXPERT ANGLE: PHYSICIAN AND PATIENT PERSPECTIVES ON KEY HCV MANAGEMENT CHALLENGES  
R. Esteban, Vall d'Hebron Hospital, Spain  
C. Gore, , United Kingdom  
A. Mangia, IRCCS 'Casa Sollievo della Sofferenza' Hospital, Italy

QUESTION TIME

Industry Satellite Symposia, Capital Suite 7-8-9

18:00-19:00  IFN-FREE FOR HCV: THE CURRENT LANDSCAPE. EXPERT OPINION ON THE PHASE III EASL BREAKING DATA

18:00-18:10  INTRODUCTION  
S. Zeuzem, J.W. Goethe University, Germany
## Scientific Programme

### 18:10-18:30
**EASY TO TREAT PATIENTS?**
S. Pol, Hopital Cochin, France

### 18:30-18:50
**HARD TO TREAT PATIENTS**
G. Foster, Queen Mary University of London, United Kingdom

### 18:50-19:00
**SYNTHESIS: ARE WE READY TO GO?**
I. Jacobson, Weill Cornell Medical College, United States

### 18:00-19:00
**CHANGING DYNAMICS IN THE SCIENCE AND CLINICAL MANAGEMENT OF PRIMARY BILIARY CIRRHOSIS: WHAT IT MEANS FOR US, WHAT IT MEANS FOR OUR PATIENTS**

**INTRODUCTION / STAGE SETTING**
D. Jones, Newcastle University, United Kingdom

**RECENT ADVANCES IN PBC: DISEASE PATHWAYS AND POTENTIAL TARGETS OF THERAPY**
U. Beuers, AMC - University Of Amsterdam, Netherlands

**CHALLENGES AND NEW OPPORTUNITIES IN THE CLINICAL MANAGEMENT OF PBC**
D. Jones, Newcastle University, United Kingdom

**QUESTIONS AND ANSWERS**

**SUMMARY AND CONCLUDING REMARKS**

### 18:00-19:30
**SONOGRAPHY COURSE ON ‘ACUTE MEDICINE’ IN HEPATOLOGY**
R. de Knegt, , Netherlands
M. Gebel, Center for Internal Medicine, Hannover Medical School, Germany

**TUTORS**
R. de Knegt, , Netherlands
M. Gebel, Center for Internal Medicine, Hannover Medical School, Germany
C. Terkamp, , Germany
A. Potthoff, , Germany
P. Taimr, , Netherlands
D. Sprengers, Academic Medical Center, University of Amsterdam, Netherlands
Sunday, 13. April 2014

Major Satellite Symposia, ICC Capital Hall

08:30-10:00 CURRENT TREATMENT OPTIONS IN HEPATITIS C: COST EFFECTIVE TREATMENT IN THE ERA OF DAAS
G. Dusheiko, United Kingdom

WELCOME AND OPENING REMARKS
G. Dusheiko, United Kingdom

WHICH PATIENTS CAN’T WAIT
G. Dusheiko, United Kingdom

TREATMENT OPTIONS IN GENOTYPE 1: WHAT IS THE REAL WORLD EXPERIENCE?
J.L. Calleja, University Hospital Puerta de Hierro Mahadahonda, Spain

TREATMENT OPTIONS IN GENOTYPE 2 & 3: DOES INTERFERON STILL HAVE A ROLE?
M. Manns, Medical School of Hannover, Germany

TREATING IN TODAY’S COST SENSITIVE WORLD
M. Makara, Hungary

CASE STUDIES & PANEL DISCUSSION

CLOSING REMARKS
G. Dusheiko, United Kingdom

Symposia, Capital Suite 7-8-9

10:30-11:30 EASL BASIC SYMPOSIUM: HCC IMMUNOTHERAPY
I. Melero, Spain

10:30-10:50 THE LIVER IMMUNE SYSTEM
N. Crispe, United States

10:50-11:10 IMMUNE REGULATION IN HCC
G. Missale, Azienda Ospedaliero-Universitaria di Parma, Italy

11:10-11:30 IMMUNOSTIMULATORY MONOCLONAL ANTIBODIES FOR THERAPY OF LIVER TUMORS
I. Melero, Spain

Symposia, Capital Suite 2-3-4

10:30-11:30 EASL CLINICAL SYMPOSIUM: ACUTE LIVER FAILURE
J. Wendon, United Kingdom

10:30-10:45 AETIOLOGY, EPIDEMIOLOGY AND DEFINITIONS
W. Bernal, Institute of Liver Studies, King’s College Hospital, United Kingdom

10:45-11:00 TIMING AND MANAGEMENT OF PATIENT PRIOR TO AND PERI REFERRAL TO TERTIARY SERVICE
F. Saliba, Hôpital Paul Brousse, France

11:00-11:15 ORGAN SUPPORT
A. Wilmer, Belgium
11:15-11:30  WHO AND WHEN TO TRANSPLANT VS WHO NOT TO TRANSPLANT  
I. Graziadei, , Austria

10:30-10:50  METABOLIC SYNDROME AND HIV  
M. Lemoine, Imperial College London, St Mary's Hospital, United Kingdom

10:50-11:10  ANTIRETROVIRAL THERAPIES AND THE LIVER IN 2014  
S. Bhagani, Royal Free London NHS Foundation Trust, United Kingdom

11:10-11:30  FUTURE CHALLENGES IN TREATING HIV/HCV CO-INFECTION  
M. Puoti, AO Ospedale Niguarda Cà Granda, Italy

10:30-11:30  EASL CLINICAL SYMPOSIUM: PRIMARY SCLEROSING CHOLANGITIS  
K. Boberg, , Norway

10:35-10:53  DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF PSC  
U. Beuers, AMC - University Of Amsterdam, Netherlands

10:53-11:11  CURRENT AND FUTURE THERAPIES OF PSC  
G. Hirschfield, University of Birmingham, United Kingdom

11:11-11:29  LIVER TRANSPLANTATION IN PSC: INDICATIONS AND RESULTS  
H. Isoniemi, , Finland

11:30-13:00  GENERAL SESSION 4 & CLOSING  
J.-F. Dufour, , Switzerland  
C. Yurdaydin, University Of Ankara Medical School, Turkey

LIVER TUMORS AND TRANSPLANTATION  
J. Belghiti, Beaujon Hospital, France

GENERAL HEPATOLOGY  
P. Ginés, , Spain

VIRAL HEPATITIS  
G. Dusheiko, , United Kingdom